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Abstract
Alternative splicing is the process by which an exon is preferentially included or excluded from an mRNA
transcript. Recent global sequencing studies have shown that >95% of the transcriptome undergoes some
form of alternative splicing. Such regulation often alters protein isoform expression, as is especially
apparent in T cells of the immune system that change their expression of RNA and protein according to
signaling cues. The focus of this thesis is on one alternative exon in the pre-mRNA of transcription factor
LEF1 and its regulation by the splicing factor CELF2. LEF1 is crucial for T cell function as it upregulates
the expression of TCRα. Upon signal induction in T-cells, CELF2 promotes the inclusion of exon 6 in LEF1
(LEF1-E6) in the final mRNA transcript. This increase in LEF-E6 inclusion generates an isoform of LEF1
that is preferentially active in promoting transcription of TCRα. CELF2 regulates LEF1-E6 inclusion upon
stimulation by increasing its binding to two conserved elements (USE60 and DSE120) in the upstream
and downstream introns flanking exon 6. My goal is to understand how the increase of binding of CELF2
to the USE60 and DSE120 upon stimulation results in an increase in LEF1-E6 inclusion. Using a
combination of in vivo minigene assays, in vitro splicing assays and UV-crosslinking assays I correlate the
binding of CELF2 to the function of the USE60 and DSE120. I show that the USE60 and DSE120 do not
work synergistically to enhance inclusion but function antagonistic to each other. The USE60 is a
repressor of splicing while the DSE120 is an enhancer. In order to achieve an increase in exon 6 inclusion
only upon stimulation, CELF2 binding is highly regulated between the USE60 and DSE120. In unstimulated
T cells, binding is biased towards the repressive USE60 and upon stimulation the increase in CELF2
binding happens purely on the activating DSE120. This bolus of CELF2 binding on the DSE120 upon
stimulation leads to an increase in exon 6 inclusion. These studies reveal a model where binding of CELF2
to the DSE120 is inhibited in unstimulated cells and this inhibition is relieved upon stimulation.
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ABSTRACT
THE ROLE OF CELF2 IN THE SIGNAL INDUCED ALTERNATIVE SPLICING OF
LEF1 EXON 6 IN T CELLS
Sandya Ajith
Kristen Lynch
Alternative splicing is the process by which an exon is preferentially included or excluded from an
mRNA transcript. Recent global sequencing studies have shown that >95% of the transcriptome
undergoes some form of alternative splicing. Such regulation often alters protein isoform
expression, as is especially apparent in T cells of the immune system that change their expression
of RNA and protein according to signaling cues. The focus of this thesis is on one alternative exon
in the pre-mRNA of transcription factor LEF1 and its regulation by the splicing factor CELF2. LEF1
is crucial for T cell function as it upregulates the expression of TCRα. Upon signal induction in Tcells, CELF2 promotes the inclusion of exon 6 in LEF1 (LEF1-E6) in the final mRNA transcript. This
increase in LEF-E6 inclusion generates an isoform of LEF1 that is preferentially active in promoting
transcription of TCRα. CELF2 regulates LEF1-E6 inclusion upon stimulation by increasing its
binding to two conserved elements (USE60 and DSE120) in the upstream and downstream introns
flanking exon 6. My goal is to understand how the increase of binding of CELF2 to the USE60 and
DSE120 upon stimulation results in an increase in LEF1-E6 inclusion. Using a combination of in
vivo minigene assays, in vitro splicing assays and UV-crosslinking assays I correlate the binding of
CELF2 to the function of the USE60 and DSE120. I show that the USE60 and DSE120 do not work
synergistically to enhance inclusion but function antagonistic to each other. The USE60 is a
repressor of splicing while the DSE120 is an enhancer. In order to achieve an increase in exon 6
inclusion only upon stimulation, CELF2 binding is highly regulated between the USE60 and
DSE120. In unstimulated T cells, binding is biased towards the repressive USE60 and upon
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stimulation the increase in CELF2 binding happens purely on the activating DSE120. This bolus of
CELF2 binding on the DSE120 upon stimulation leads to an increase in exon 6 inclusion. These
studies reveal a model where binding of CELF2 to the DSE120 is inhibited in unstimulated cells
and this inhibition is relieved upon stimulation.
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CHAPTER 1: INTRODUCTION
Alternative splicing and spliceosome assembly
The central dogma of biology describes a linear progression of events that starts with DNA
(genes) that is transcribed into messenger RNA (mRNA) that is translated into protein. This 1:1:1
association between the three states means that the proteomes of humans and the nematode C.
Elegans should be relatively equal with ~20,000 protein for 20,000 RNA for ~20,000 protein-coding
genes. However, global studies of RNA and protein have shown that diversity in both these realms
goes well beyond the 1:1:1 ratio. It is this diversity that accounts for how although humans have a
similar number of genes as worms - humans are much more biologically complex having greater
proteomic and cellular diversity3.
A major mechanism by which this diversity is achieved is at the level of RNA during a
process called splicing. Splicing is a co-/post-transcriptional process by which the introns in a premRNA transcript are excised and the exons, which contain the protein coding information, are
ligated together to form a mature transcript. However, various versions of a transcript can be
created by regulating not only intron removal but exon fate as well. During the process of splicing,
through a system of regulatory sequences and proteins, certain exons can be preferentially
included or excluded, leading to many isoforms of a protein from the same coding gene. This is
called alternative splicing and global sequencing studies have shown that this process occurs in
>95% of coding genes4,5
The ability to create and regulate the expression of functionally diverse isoforms makes
alternative splicing a powerful tool used by the cell to dictate its internal and external environment
in response to various stimuli. The mechanisms underlying how an exon is alternatively spliced in
response to developmental signals are based on a network of regulatory proteins that control the
splicing machinery. The chemistry of splicing is undertaken by the spliceosome, a RNA-protein
macro-molecular machine whose final catalytic conformation is achieved on the pre-mRNA
transcript via a step-wise assembly process.
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The spliceosome is composed of 5 distinct RNAs - U1-2 and U4-6 - which associate with
~145 proteins to form ribonuclear protein complexes (snRNPs) 6,7. These snRNPs interact with
varying sequences on the intron and exon - particularly the 5’ and 3’ Splice Sites (ss), PolyPyrimidine Track (PPT) and the Branch Point Sequence (BPS). Besides the splice site consensus
sequences, the BPS has a conserved adenine whose 2’OH performs the first nucleophilic attack
and is therefore crucial to the catalytic activity of the final spliceosomal complex. The earliest step
in the process is the formation of the E (early) complex. It involves the binding of U1 snRNP to the
5’ss, U2AF heterodimer (U2AF 35 and 65) to the PPT and 3’ss. This is then converted into the A
complex by the ATP-dependent addition of U2 snRNP to the 3’ss. This is followed by the
recruitment of the remaining snRNPs U4-U6 (tri-snRNP) to form the B complex. Finally, after a
series of re-arrangements the splicing competent C-complex (catalytic complex) is formed with the
release of U1 and U4 snRNP6,8–10. (Figure 1.1). The catalytic complex is now capable of enabling
the nucleophilic attacks required for intron excision and lariat release.
Regulation of alternative splicing via cis- and trans-acting factors
It is important to note that the interactions that drive spliceosome assembly are largely
weak, such that every step can be assisted or impeded by additional regulatory proteins. In all
cases of alternative splicing that have been studied in detail, the regulation of exon fate involves
trans-acting regulatory proteins interacting with cis-acting sequences on the pre-mRNA transcript
as well as those in the splicing machinery. These synergistically lead either to promotion of
spliceosome assembly and exon inclusion or to interference with the assembly process and exon
exclusion1,11,12. These interventions by cis- and trans- acting elements can occur at various steps
in the assembly process for example:
Splice Site recognition: The earliest step that can be regulated is the recognition of splice sites
by the splicing machinery. Opportunities for regulation can arise from weak splice site strength
(too divergent from the consensus sequence), steric blocking by other proteins or even RNA
secondary structure12–15.
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Late spliceosome assembly: Regulation can also occur after splice site recognition and the ATPdependent addition of U2 snRNP to the BPS. In order for C-complex formation, interactions
between U1 and U2 have to occur across an intron, creating an “intron-defined” complex that is
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required for catalysis. In higher eukaryotes however, studies have shown that the spliceosome first
forms around the exon, creating an “exon-defined” complex8,16. Regulatory proteins can facilitate
the conversion of exon- to intron- defined complex and cause inclusion and can also act to stabilize
the exon-defined complex causing exon exclusion. Regulation can also occur after intron-definition
is achieved by interfering with the recruitment of the tri-snRNP12,17–19.
Considering the ubiquitous nature of alternative splicing and the various mechanisms by
which spliceosome assembly can be regulated to achieve it, it comes as no surprise that a wide
variety of cis-acting Sequence Regulatory Elements (SREs) and trans-acting regulatory proteins
have been identified that typically bind to non-splice site sequences to control spliceosome
assembly. SREs are varied in their lengths and depending on where they bind and the effect they
have on an alternative exon, these cis-acting elements can be Exonic Splicing Enhancers or
Inhibitors (ESEs or ESSs) or Intronic Splicing Enhancers or Inhibitors (ISEs or ISSs)2,11,12,20.
The trans-acting regulatory proteins are mostly RNA Binding Proteins (RBPs) that bind to
SREs and regulate alternative splicing events. Unlike SREs, RBPs cannot be broadly categorized
into enhancers and repressors as their function is highly dependent on the context of the exon. A
single RBP can positively or negatively influence hundreds of alternative splicing events in a cell.
Conversely, the length of the SRE permitting, a single SRE can bind many RBPs that function in
combination to influence exon fate.
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There are approximately 50 RBPs that have been shown to directly interact with pre-mRNA and
influence alternative splicing in mammals 3,21,22.

Each alternative splicing event is under the

combinatorial control of many RBPs that bind SREs and act cooperatively or antagonistically to
ultimately decide whether an exon is included or excluded from the final transcript 2,3,21,22 (Figure
1.2).
Alternative Splicing in the Immune System
The regulation of alternative splicing plays a crucial role in processes like the epithelialmesenchymal transition, regulation of action potentials, heart development and, of importance to
this thesis, the regulation of T-cell function in the immune system 21,23–25. T-cells are lymphocytes
that play a crucial role in adaptive immunity. Pre T cells develop from pluripotent stem cells in the
red bone marrow that then travel to the thymus for maturation. The maturation process involves
the expression of the T cell receptor (TCR) as well as either the CD4 or CD8 protein on its plasma
membrane, termed CD4 or CD8 T cells. In the presence of a foreign antigen, TCR in conjunction
with either the CD4 or CD8 protein bind antigen and trigger a signaling cascade that is the start of
an immune response26,27.
This signaling cascade leads to a large number of changes within the T cell, such as
increased expression of TCR, increased proliferation and cytokine production and secretion to
name a few. Therefore, the effectiveness of the immune system depends on its ability to orchestrate
large changes in protein expression in response to antigen signaling. Several studies that
investigated changes in alternative splicing in T cells using high-throughput RNA sequencing (RNAseq) or microarrays have shown that one of the ways T cells respond to external signaling is through
changes in alternative splicing25,28–30. In a 2012 study by the Lynch Lab to which I contributed,
high-throughput RNA sequencing (RNA-seq) was used to highlight the alternative splicing networks
involved in regulating the start of an immune response. The study used a Jurkat derived model T
cell line31, called JSL1, as well as primary human T cells to show that T cell stimulation caused
significant changes in the isoform profile of 178 exons in 168 genes25. A handful of these genes
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have been studied further and illustrate the various ways alternative splicing is used to regulate T
cell activation.
The most studied alternative splicing event is the regulation of exons 4, 5, and 6 of the
CD45 gene. CD45 is a transmembrane tyrosine phosphatase responsible for regulating antigen
receptor signaling and lymphocyte development. Upon activation of T cells, exon 4, 5 and 6 are
excluded, leading to the expression of an inactive form of the phosphatase. The repression of these
exons is caused by ESSs present in all three exons, however mechanistic details are only available
for exons 4 and 5. In the case of exon 4, this ESS binds to hnRNPL, hnRNPLL and PSF of which
the latter two are responsible for signal induced exon exclusion. In the case of exon 5, SRSF1
binds an ESE within the exon but it’s activating effect is displaced upon stimulation by the binding
of hnRNP L and PSF to two flanking ESSs17,32–35.
The regulation of CD45 exons 4 and 5 highlight the complexity involved in the coordination
of SREs and the RBPs that bind to them. Besides CD45, mechanistic details are only available for
the signal induced regulation of four other genes - CD3ζ exon 8 by SRSF136, Fas exon 6 by TIA137, CD44 exon v5 by Sam6838 and the focus of this thesis, LEF1 exon 6 by CELF239.
CELF2 is a regulator of alternative splicing
CELF2 is part of the CUG and ETR-3 Like Factor (CELF) family of proteins of which there
are 6 members. All members of this family are characterized by three RNA Recognition Motifs
(RRMs). RRM1 and 2 lie at the N terminus of the protein and RRM3 lies at the C terminus with a
linker domain linking RRM 2 to 3. CELF2 shows high similarity (>90%) with CELF1 within their
RRMs but diverge greatly in the linker domain40,41. Several studies have shown that the RRMs of
CELF proteins bind UG-rich sequences. Structural studies of the RRMs of CELF1 show all three
RRMs bind UGUU motifs. However, RRM1 and 2 have higher affinity for UG-rich RNA when linked
together than when separate. Additionally, part of the linker domain was shown to greatly increase
RRM3’s affinity for RNA, showing that this region could be very important to function42–47.
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There are two alternative splicing events important to CELF2 structure and expression.
CELF2 is involved in autoregulation of its own transcript by repressing exon 6 inclusion. If translated
this would create a protein that is truncated at RRM2 as the skipping of exon 6 seems to cause a
reading frame shift that introduces a premature stop codon and triggers the Nonsense Mediated
Decay(NMD) pathway48. Additionally, there is evidence for the regulation of exon 14 that encodes
for the beginning of RRM3. Molecular Dynamics coupled with NMR studies imply that the skipping
of this exon would make RRM3 incapable of binding RNA. This isoform therefore has differential
effects on alternative splicing as opposed to its full length protein. This isoform has been shown to
be expressed at significant quantities only in the kidneys and liver 49.
Unsurprisingly for a RNA binding protein with three RRMs CELF2 plays large roles in
alternative splicing and mRNA stability. CELF2’s roles in mRNA stability are of particular interest
as a target for disease therapeutics. CELF2 stabilizes the poly-glutamine extended Androgen
Receptor (AR) mRNA in Spinal and Bulbar Muscular atrophy and targeted silencing of CELF2
successfully led to decay of the toxic AR mRNA50. CELF2 is of potential interest for cancer
therapeutics as it hyper-stabilizes the anti-apoptotic factors COX2 and MCL1 mRNA in pancreatic
and colon cancer cells, thereby inhibiting their translation and encouraging apoptosis 51–53.
In the case of alternative splicing, CELF2 has been shown to act as both an activator and
repressor of exon inclusion. Besides LEF1-E6 there are 11 mechanistic studies of CELF2
regulating alternative splicing. An example of CELF2 activating exon inclusion is the regulation of
Cardiac Troponin T (cTNT)’s exon 5 which is preferentially included in embryonic striated muscle
but excluded in adult tissue. The isoforms created from the alternative splicing of exon 5 confer
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different contractile properties to the muscle tissue. CELF2 ensures that exon 5 is included in
embryonic tissue by binding to a UG-rich element downstream of exon 5 and acting across the
exon to stabilize the binding of U2snRNP to the 3’ss and encourage exon definition54–56.
An informative example of CELF2 repressing exon inclusion comes from exon 9 of the
Cystic Fibrosis Transmembrane Regulator (CFTR) gene. CELF2 binds to a UG-rich sequence
upstream of exon 9 and represses exon inclusion by displacing binding of constitutive splicing factor
U2AF65 from the PPT. This repression was dependent on the rate of transcription as a slow rate
of transcription allowed for greater CELF2 recruitment and binding upstream and greater exon
skipping. A faster elongation rate presumably reduced the amount of CELF2 recruited upstream
and thus, less displacement of U2AF6557.
Based on all published studies of CELF2 regulating alternative splicing, it seems to have a
positional dependence on how it influences exon inclusion. CELF2 binding upstream of the
alternative exon as in CFTR exon 9, NMDAR1 exon 5 (N1), α actinin exon NM and CELF2’s own
exon 6 leads to exon skipping48,57–59. However, CELF2 binding downstream of an alternative exon
as in cTNT exon 5 and NMDAR1 exon 21 (C1), encourages exon inclusion54,55,59. Global
sequencing studies and MS2 tethering assays that correlate RBP binding to exon fate have
revealed that a significant number of splicing factors including PTB, SRSF1,2,6,7,and10, TIA-1,
Fox2α, FUS, hnRNPA1 and hnRNP F/H show evidence for positional dependent effects on exon
fate60–64. Unpublished work from our lab that investigated CELF2 binding and alternative splicing
regulation on a global scale in T cells confirms that CELF2 functions through a similar mechanism.
In the model T cell line JSL1 and in developing thymocytes, CELF2 expression increases
upon signal induction through both an increase in transcription and mRNA stability. The increase
in CELF2 expression is dependent on the NF-κB signaling pathway. The increase in CELF2 levels
have wide effects in alternative splicing changes that happen during signal induction affecting a
third of all splicing events that undergo a signal induced change 65. One of the signal induced
splicing events that requires CELF2 is the preferential increase of exon 6 of LEF1 upon T cell
stimulation.
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LEF1 exon 6 and its effect on TCRα expression
Lymphoid Enhancer-binding Factor 1 (LEF1) is a transcription factor involved in the
regulation of a wide variety of cellular processes. More specifically, it regulates many
developmental programs including that of the hair follicle, teeth, osteoblasts and mammary
glands66–69. It has also been implicated in the progression of several cancer populations including
gastrointestinal and pancreatic cancer66,70. It is characterized by a β-catenin binding domain called
the Activation Domain (AD) at its N-terminus and a High Mobility Group (HMG) DNA Binding
Domain (DBD) with a Nuclear Localization Signal (NLS) at its C-terminus. The N and C termini are
separated by a Context Regulatory Domain that is encoded by alternative exon 670,71 (Figure 1.4).
In T cells, LEF1 is crucial for upregulating the expression of T-cell Receptor Alpha (TCRα).
TCRα, along with TCRβ, is required to form a mature TCR which is crucial for its response to
antigen binding and its maturation in the thymus. LEF1, through its CRD, forms protein-protein
interactions in an enhanceosome complex that activates TCRα expression. LEF1 exon 6 (LEF1E6) encodes part of the CRD and its exclusion from the final transcript creates an isoform of LEF1
that cannot upregulate TCRα (Figure 1.4 panel A).
Previous work done in the lab established that there is a preferential increase in inclusion
of exon 6 during thymic development when immature T-cells transition from the Double negative
(Dn) to double positive (Dp) state. This is recapitulated in the JSL1 cells when stimulated with the
phorbol ester PMA. The preferential inclusion of exon 6 correlated with increased TCRα expression
in both cases39,72,73. Additionally, Mallory et al was able to show that the enhancement of TCRα
was a direct result of exon 6 splicing. The authors used a splice site morpholino to force exclusion
of exon 6 and this resulted in a significant decrease in TCRα mRNA39. Therefore the mechanism
by which LEF1 isoform choice is regulated by the alternative splicing of exon 6 has important
implications for T-cell function and development (Figure 1.4).
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The regulation of LEF1-E6 by CELF2 in T cells
The same study by Mallory et al narrowed down the required SREs for regulation of LEF1E6 inclusion upon T cell stimulation to two intronic elements upstream and downstream of the exon.
Even replacing the exon (∆exon) did not affect enhancement of LEF1-E6 upon stimulation. The two
intronic elements were called the Upstream Sequence Element, that is 60 nucleotides (nts) long
(USE60), lies immediately upstream of exon 6 and includes the 3’ss and the Downstream
Sequence Element that is 120 nts long (DSE120) and lies 31 nts downstream from exon 6. These
sequences are highly conserved and rich in UG motifs, which are known CELF2 binding sites.
CELF2 binds the USE60 and DSE120 and is functionally required for exon inclusion (Figure 1.5).
Importantly, upon stimulation, the binding of CELF2 to these elements increases. The study
showed that a 50% reduction in CELF2 protein by shRNA resulted in a 2-3 fold decrease in LEF1-
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E6 inclusion and a corresponding decrease in TCRα mRNA expression39. In this thesis, I extend
this study by Mallory et al by investigating the mechanism by which CELF2 interacts with the LEF1
pre-mRNA transcript to facilitate the preferential inclusion of variable exon 6 upon T cell stimulation.
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CHAPTER 2: THE USE60 AND DSE120 ARE SUFFICIENT FOR SIGNAL
INDUCED ENHANCEMENT OF LEF-E6 INCLUSION
Introduction:
Splicing is a complicated process that is under the influence of a large number of cis and
trans-acting factors. Depending on the mechanism by which they exert their influence, splicing
factors can either act on maintaining levels of inclusion in the unstimulated state (basal) levels or
play a role in a signal induced change in exon inclusion. An informative example is the CD45 gene,
whose exon 4 is regulated in a signal-dependent manner in T cells. Three splicing factors, hnRNP
L, hnRNP LL and PSF act on exon 4 to repress exon inclusion but not all of them are involved in
the signal induced repression. hnRNP L mediates basal levels of inclusion in unstimulated T cells
by binding to an ESS in exon 4 and its effect remains unchanged upon stimulation. hnRNPLL and
PSF, however, only bind the ESS in stimulated cells and cause further repression of CD45 exon
434,35,74.
In the case of CD45 exon 4, even though all three proteins bind to a single repressive
element, the ARS, they have very distinct mechanisms of repression, with hnRNP L acting in both
unstimulated and stimulated cell while hnRNP LL and PSF acting only in stimulated cells .
Specifically, considering how many complex mechanisms can occur even on a single signal
responsive element, it is imperative to distinguish between those that act on basal splicing and
those that act on signal induced changes. Therefore, determining the minimum sequence
requirements (cis factors) required for a signal-induced change in splicing is an important first step
in reducing the complexity of the system. These minimum sequence requirements are crucial in
being able to isolate the mechanism responsible for the signal induced change from the myriad of
other mechanisms at play.
Previously Mallory et al. concluded that 2 intronic SREs, the USE60 and DSE120, were
required for the signal induced enhancement of LEF1-E6 inclusion. The authors could not conclude
that these regulatory sequences were sufficient for this regulation because the minimum construct
used retained additional LEF1 sequences. In particular, the requirement of the sequence that
connects the 5’ss to the DSE120, called the Downstream Connecting Sequence (DCS) for the
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signal induced regulation of LEF1-E6 had not been tested in vivo. Here I describe the use of
minigene assays in determining whether the DCS is required for enhancement of LEF1-E6
inclusion. Establishing the most minimal construct required for LEF1-E6 enhancement upon
stimulation is imperative to being able to discover and understand the mechanism by which it
occurs.
Results:
The DCS is a stretch of 31 nucleotides that extends from after the 5’ splice site to the
DSE120 (Figure 2.1). It is not as conserved as the DSE120, with the highest conservation found in
the 8 nucleotides immediately after the 5’ss (Figure 2.1, nucleotides with asterisks above them). In
order to determine whether the DCS is required for signal induced enhancement of LEF1-E6
inclusion, I created a minigene construct in which the DCS was replaced with a 38 nt heterologous
sequence shown previously in the lab to have no effect on splicing regulation (∆DCS).
A minigene is a simplified construct that contains the variable exon in question along with
the relevant amount of flanking intronic sequence. The sequence of interest is amplified out of
genomic DNA, inserted into an expression vector and placed under the control of a T7 promoter.
The variable exon and relevant intronic sequences are flanked by two constitutive exons from a
known and tested gene. These minigenes can be used for in vivo studies by transient transfection
into a cell line of choice or for the construction of stable cell lines 75.
For this study, the alternative exon and intronic sequences are flanked by β-globin
constitutive exons 1 and 2. The ∆DCS, 90/160, ∆exon and 90/40 minigenes were transfected into
the Jurkat-derived T-cell line called JSL1. The minigenes were tested under unstimulated and
stimulated conditions. JSL1 cells were stimulated using Phorbol-12-myristate-13-acetate (PMA),
which has been previously shown to mimic T-cell activation through the TCR76. After 72 hours of
stimulation, RNA was extracted from unstimulated and stimulated cells and Reverse TranscriptasePolymerase Chain Reaction (RT-PCR) with radio-labeled primers was used to amplify the region
in between and including the constitutive exons. The reactions were visualized on a denaturing
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PAGE gel where the RT-PCR products are separated by size. The % exon included and % exon
excluded for each condition was quantified by densitometry using a phosphor-imager. A measure
called Fold Activation (FA) was used to accurately measure the amount that exon inclusion
increases

after

stimulation.

FA

is

calculated

by

using

the

formula:

FA

=

(%exclusion/%inclusion)unstimulated / (%exclusion/%inclusion)stimulated. This accounts for any variability
in basal levels of inclusion that can skew the measurement. Based on results from Mallory et al
and previous experience in the lab with LEF1 minigenes, a FA above 2.5 is considered a signal
responsive minigene.
Figure 2.1 shows that the ∆DCS increased basal levels of inclusion relative to the 90/160
minigene, which implies the presence of an Intronic Splicing Silencer (ISS) in the DCS. However,
∆DCS did not significantly affect signal induced enhancement of exon 6 inclusion as the fold
activation was comparable to the 90/160 and ∆exon minigenes i.e well above the 2.5 fold. This
suggests that the DCS influences basal levels of inclusion but is not responsible for the increase in
exon inclusion upon PMA stimulation (Figure 2.1).
However, upon closer inspection of the heterologous sequence used in the ∆DCS, I noticed
that it contained 4 of the 8 conserved residues of the DCS, in a similar position as the DCS
(Figure2.2). The residues of interest were AGGT and therefore to ensure that those 4 residues did
not play a part in LEF1-E6’s signal induced regulation, I used a minigene construct that substituted
the conserved G’s in the DCS to C’s (90/160 mut2). The 90/160mut2 minigene had higher levels
of basal inclusion, similar to the ∆DCS, but did not have any effect on FA levels. The minigene data
from the 90/160mut2 minigene taken together with the ∆DCS minigene confirm that the DCS is not
required for the signal induced enhancement of LEF1-E6.
If the minimal requirement for regulation of LEF1-E6 is the USE60 and DSE120, it is
important to confirm whether the location of these sequences is important to regulation or whether
they serve as a recruiting tool to concentrate more CELF2 in the region of LEF1-E6. In order to test
whether USE60 and DSE120 need to flank LEF1-E6 I created a minigene that moved the DSE120
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upstream of the USE60 (DSE-I1). If the DSE120 was functioning just as a tool to recruit CELF2 to
the region of exon 6, this displacement of the motif would not affect signal induced exon inclusion.

.
However, if the binding of CELF2 downstream was crucial to the mechanism of exon 6
inclusion, there would be no signal dependent increase in inclusion in DSE-I1. Figure 2.3 shows
that there is no significant increase in exon 6 inclusion upon PMA stimulation in DSE-I1 as the FA
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remains close to that of the ∆DSE120 in DSE-I1 as opposed to the higher FA of the WT construct.
This confirms that the location of the DSE downstream of the exon and hence binding of CELF2
downstream of the exon is required for this regulation.

Discussion:
The minigene studies interrogating the requirement of the DCS have confirmed that the minimal
sequence requirements for the signal induced enhancement of LEF1-E6 is the USE60 and
DSE120. Additionally is it important to stress that the USE60 and DSE120 are necessary and
sufficient for signal induced inclusion of LEF1-E6.
Having regulatory elements that bind the same protein flank an exon to cause inclusion has
not been described in the literature before. The most studied example of splicing regulation by two
cis elements in the flanking introns of an alternative exon is Poly-pyrimidine track binding protein’s
(PTB) repression of c-src’s N1 exon18,77,78. PTB binds these two sequence elements to induce
exclusion of the N1 exon in non-neuronal cells, where PTB expression is higher than in neuronal
cells. Both these sequences are required for repression and studies have shown that an exondefined spliceosomal complex is prevented from being converted to a splicing competent introndefined complex18,78.
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However, the mechanism by which this is achieved is unclear, so is the reason for requirement
of both upstream and downstream elements. It is known that PTB interacts with stem-loop 4 in the
U1 snRNA but it is unclear which PTB molecule (ones bound upstream or downstream) is involved
in this interaction or whether the interaction itself is required for repression. It is possible that this
interaction with U1 inhibits intron-defined interactions from forming, but this is yet to be confirmed.
What is known about PTB’s regulation is that binding downstream is required for PTB
association upstream. This suggests a model where either one PTB molecule forms bridging
interactions across the N1 exon or multiple PTB molecules interact with each other across the exon.
This would result in the exon being looped out leading to disruptions in normal splicing
interactions77,79,80.
PTB’s regulation of c-src’s N1 exon is a good template by which to evaluate CELF2’s regulation
of LEF1-E6 alternative splicing. The interactions made by CELF2 with the splicing machinery are
still unknown, however, just like PTB binding around the N1 exon, CELF2 binds SREs in the two
flanking introns. The N1 exon is included in neurons where the expression of PTB is low and is
excluded in non-neuronal cells where PTB levels are high78–80. An increase in PTB binding to the
two intronic elements leads to an increase in exon exclusion. In LEF1-E6, an increase in CELF2
binding leads to an increase in exon inclusion. Mallory et al established that if the USE60 and
DSE120 are radiolabeled and subjected to UV crosslinking in unstimulated and stimulated JSL1
nuclear extract, CELF2 is the only protein that increases binding upon stimulation. These
experiments were done with the sequences in isolation, without the context of the rest of the RNA.
It would be informative to know the pattern of CELF2 binding in the context of LEF1-E6 when both
the USE60 and DSE120 are present. In the case of PTB, the downstream element is required to
stabilize PTB binding upstream 79. Is CELF2 similar to PTB wherein it requires both elements to
bind to the RNA at all or do the USE60 and DSE120 function independently? This will be addressed
in chapter 3 of this thesis.
One of the first steps towards deciphering the mechanism behind LEF1-E6 activation is to
determine the function of the USE60 and DSE120. We know from PTB that the regulatory elements
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ultimately lead to exclusion, however a more global study has shown that PTB binding downstream
is more associated with inclusion of exon while upstream and exonic binding correlate with
exclusion. The authors were also able to convert an exon that was activated by PTB binding
downstream to being repressed by adding a PTB binding element upstream. The repression was
most robust when there were twice the number of PTB sites downstream versus upstream 63.
Determining whether the USE60 and DSE120 are ISE’s or ISS’s would be crucial to interpreting
downstream studies on the mechanism of LEF-E6 activation and its interaction with spliceosomal
components. Chapter 4 of this thesis will focus on the functions of the USE60 and DSE120.
Another possibility is the requirement for another splicing factor that regulates CELF2 binding
to the USE60 and DSE120. In the case of PTB, the exon defined complex that forms on the N1
exon in non-neuronal cells contains different proteins than the one that forms in neuronal cells
where N1 is included. This could mean the involvement of other factors that clarify the role of the
upstream and downstream elements18. Chapter 5 and 6 of this thesis addresses that possibility in
CELF2’s regulation of LEF1-E6.
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CHAPTER 3: CELF2 BINDING TO THE USE60 AND DSE120 WITHIN THE
CONTEXT OF LEF1 EXON 6
Introduction:
The enhancement of LEF1-E6 inclusion upon T cell stimulation is regulated by two ciselements, one upstream of the exon called USE60 and one downstream of the exon called DSE
120. The splicing factor CELF2 interact with these two elements in unstimulated cells and upon
stimulation there is an increase in CELF2 binding to these elements which leads to an increase in
exon 6 inclusion. These experiments were done with the USE60 and DSE120 in isolation and
outside the context of the exon they would be regulating. The sequence that would connect the
USE60 and DSE120 could greatly influence the degrees to which CELF2 has access to these
sequences. Therefore it is possible that within the context of the exon, the pattern of binding of
CELF2 to the USE60 and DSE120 might be biased for one over the other.
Whether CELF2 binding between the USE60 and DSE120 is distributed equally or whether
one sequence element is favoured over the other, can have large impacts on the influence CELF2
is having on the exon. There is a large body of literature confirming that the regulation of splicing
by trans-factors is highly context dependent. Whether a splicing factor is a repressor or an activator
can depend on whether it binds in the upstream intron, the exon or the downstream intron. Global
studies that correlate protein binding with alternative exon fate have shown that the Rbfox family of
proteins81,82, TIA family of proteins64, PTB63, SRSF1060, PUM2 and QKI83 all show positiondependent effects on exon inclusion. Additionally, unpublished data from other members of the lab
suggest that CELF2, also has positional effects on splicing. Since the crux of the mechanism behind
the enhancement of LEF1-E6 upon stimulation lies in the differential binding of CELF2 to the
USE60 and DSE120, accurately mapping its binding in the unstimulated and stimulated state in the
context of LEF1-E6 is vitally important.
Results:
Previous work by Mallory et al showed via Ultra-Violet (UV) crosslinking studies in
unstimulated and stimulated nuclear extract that CELF2 binds the USE60 and DSE120 in the
unstimulated and stimulated state. UV-crosslinking is a standard procedure used to form stable
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covalent crosslinks between nucleic acids and protein that are within a few angstroms of each
other. Radio-labeled USE60 and DSE120 RNA is radio-labeled and incubated with JSL1 Nuclear
Extract (NE) under splicing conditions and cross-linked with UV light (254nm). The RNA is then
digested using RNases (T1 and A) and the proteins are separated on a denaturing SDS-PAGE gel.
Proteins that bound to the RNA were detected by autoradiography as they are covalently linked to
radio-labeled nucleotide. UV crosslinking is followed by Immunoprecipitation (IP) of CELF2 and
control antibodies. Figure 3.1, adapted from Mallory et al, shows that concurrent with the
enhancement of exon 6 inclusion upon stimulation, CELF2 binding to both sequences is enhanced
upon stimulation39 and the current hypothesis is that it is this increase in binding that leads to an
increase in exon 6 inclusion. (Figure 3.1).
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To quantify how robust CELF2’s interaction with these sequences are, I performed ElectroMobility Shift Assays (EMSA) using bacterially expressed his-tagged CELF2 (his-CELF2) and
radiolabeled USE60 and DSE120 (Figure 3.2 panel B). The radiolabeled RNA is incubated with
his-CELF2 to allow complex formation. The complexes are visualized using autoradiography on a
native gel. Figure 3.2 shows that the USE60 and DSE120, in isolation from each other and the
exon, are potent binders of CELF2 and bind with an apparent Kd (dissociation constant) of 160nM.
For comparison, high affinity CELF2 binding sequences (2x and 4xUGUU), acquired from
a Systematic Evolution of Ligands by Exponential Enrichment (SELEX) study by Faustino et al,
was used84. The 2xUGUU and 4xUGUU have repeated instances of a sequence rich in UG motifs.
The 2xUGUU sequences is approximately 60 nucleotides in length and serves as a length control
for the USE60 while the 4xUGUU is approximately 120 nucleotides and serves as a length control
for the DSE120. 2x has a total of 28 UG di-nucleotides and consequently 4x has a total of 56 UG
di-nucleotides. This is substantially larger than the USE60 with 8 UG di-nucleotides and the
DSE120 with 19 UG dinucleotides. Figure 3.2 shows that the 2xUGUU is a weak binder of hisCELF2, relative to the USE60, and does not saturate the RNA even at 1800nM of his-CELF2. The
4xUGUU however binds with an apparent Kd of 380nM and is closer in binding potency to the
USE60 and DS120. The USE60 and DSE120 can therefore be categorized as high affinity CELF2
binding sequences. (Figure 3.2)
Considering the USE60 and DSE120 have equal affinity for CELF2 suggests a simplistic
model where the increase in CELF2 binding upon stimulation occurs equally at both elements.
However, this ignores the effect the LEF1-E6 regulatory landscape could have on protein binding,
the least of which involves having both the USE60 and DSE120 present in the same substrate. In
order to monitor CELF2 binding in the context of the LEF1 regulatory landscape, I repeated the UV
crosslinking experiments with a wild-type (WT) construct that contained the USE60-exon6-DSCDSE120 sequences (Figure 3.3). Figure 3.3 shows that many proteins bind the sequences in and
around exon 6 however, the most predominant change is the band around 50kDa. In order to
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confirm that the 50kDa band that increased upon stimulation was CELF2, I used a CELF2 antibody
to IP CELF2 from the UV crosslinking reactions. Having confirmed that CELF2 binds the USE60exon6-DSC-DSE120 sequence and that it’s binding increases upon stimulation, I used constructs
that had either the USE60 or the DSE120 replaced with heterologous sequence (alt60-exon6-DCSDSE120 = USE60 and USE60-exon6-DCS-alt120 = DSE120) to determine which regulatory
element was being bound by CELF2 in each condition (Figure 3.3).
Figure 3.3 shows that in the unstimulated state USE60 is still capable of binding CELF2
but at slightly lower levels than WT (Figure 3.3 panel C). Importantly, the USE60 maintains the
increase in CELF2 binding upon stimulation that is seen in the WT substrate. In unstimulated
extract the DSE120 also binds CELF2 close to WT levels. Strikingly however, the DSE120 does
not bind more CELF2 upon stimulation, especially when compared to WT and USE60. Although
CELF2 is capable of binding both sequences, in the absence of the DSE120, CELF2 binds the
USE60 but is incapable of any increased binding upon signal induction. However, in the absence
of the USE60, CELF2 binds the DSE120 in unstimulated cells and can increase this binding upon
stimulation. This suggests that in unstimulated cells, CELF2 binds to the USE60 and minimally to
the DSE120 but the key signal-induced increase of CELF2 binding upon stimulation is localized to
the DSE120.
Discussion:
The comparison of protein binding with and without the context of the exon highlights the
complexity of RNA-protein interactions and the various factors that could influence them. Having
more of the regulatory landscape of LEF2-E6 present during the experiment not only affects the
pattern of binding of CELF2 but also is a powerful tool by which to accurately map where CELF2
binds in different cell states. Figure 3.3 convincingly shows that even though the USE60 and
DSE120 are high affinity binders of CELF2 outside the context of LEF1-E6, within the context of
the exon there is a preference for the DSE120 in stimulated cells. This is in contrast to the model
from Mallory et al showing that there isn’t an equal increase in CELF2 binding on both elements
upon stimulation but a preferred increase on the DSE120 over the USE60 (Figure 3.3 panel D).
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Additionally, it is important to note that within the context of LEF1-E6, CELF2 is capable of
interacting with each element independent of the other as replacement of the USE60 did not
interrupt CELF2’s interaction with the DSE120 and vice versa. The fact that the USE60 and
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DSE120 can bind independently is very unlike PTB’s regulation of csrc’s N1 exon79, where the loss
of the downstream regulatory element results in a loss of PTB binding in the upstream element. In
that case both sites are important to stabilize the interaction. That fact the USE60 and DSE120 are
not both required to stabilize CELF2 binding is intriguing because, both elements are required to
enhance LEF1-E6 inclusion upon stimulation39. In order to understand this mechanism, it is
important to be able to correlate binding to function. Categorizing the USE60 and DSE120 as ISS’s
or ISE’s, in the context of LEF1, would shed light on the significance of the change in binding upon
stimulation.
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CHAPTER 4: FUNCTION OF THE USE60 AND DSE120
Introduction:
One of the outstanding questions about the signal induced enhancement of LEF1-E6 is the
specific functions of the USE60 and DSE120 i.e are they ISSs or ISEs. The fact that CELF2 binds
preferentially downstream upon stimulation implies that the USE60 and DSE120 have differing
functions, but it is also possible that they are both enhancing, with the DSE120 being a more robust
activator of splicing. There aren’t any instances in the literature where CELF2 binds on either side
of an exon however there are many examples of CELF2 binding on either the upstream or
downstream intron. Except for one instance involving one of the mutually exclusive exons SM and
NM of α-actinin59, every instance of CELF2 regulation of cassette exons that has been studied in
molecular detail has shown that CELF2 binding upstream causes exon exclusion 57,58 while CELF2
binding downstream of an alternative exon causes inclusion55,58,84.
To analyze the effects of the USE60 and DSE120 on exon splicing I used in vitro splicing
assays with constructs that lacked one or both the elements. I then corroborated the in vitro splicing
results with the exon inclusion levels obtained from the in vivo minigene assay. Clarifying what the
functions of the USE60 and DSE120 are, in the context of LEF1, can help guide and interpret
experiments that probe how CELF2 binding to these elements is regulated between unstimulated
and stimulated cells. To correlate the functions of the USE60 and DSE120 with the regulation of
CELF2 binding in the unstimulated and stimulated state, I used recombinant CELF2 expressed
under each condition in RNA binding experiments. Together these experiments inform a model for
how CELF2 regulates the enhancement of LEF1-E6 upon stimulation.
Results:
In order to determine whether the USE60 and DSE120 work in unison to cause exon
inclusion or whether they follow the apparent positional dependent rules suggested by the literature,
I used an in vitro splicing assay to monitor splicing in LEF1 RNA templates and compare the WT
construct that contained both the USE60 and DSE120 (USE60/DSE120) with constructs in which
the USE60 was deleted (/DSE120) or the DSE120 was replaced (USE60/alt120). When compared
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to the WT construct (USE60/DSE120) and a construct that lacks both elements(/alt120), the RNAs
with only the USE60 or DSE120 can shed some light on how the they function in the alternative
splicing of LEF1-E6.
The in vitro splicing assay first involves the in vitro transcription of USE60/DSE120,
/DSE120, USE60/alt120 and /alt120 RNA. The RNA is then incubated in nuclear extract to allow
splicing to occur before using radio-labeled RT-PCR to amplify spliced and unspliced products.
Splicing products are monitored on denaturing gels using autoradiography (Figure 4.1 panel A).

28

Figure 4.1 shows the results of the assay after incubation for 90 minutes in nuclear extract. Deleting
the USE60 caused an increase in splicing of the downstream intron, showing that the USE60
represses splicing. However, replacing the DSE120 caused a decrease in splicing of the
downstream intron, making the DSE120 an activator of splicing.
It is possible that the increase of splicing seen after the deletion of the USE60 is due to the
absence of any sequence upstream of the exon. This could encourage intron definition on the
downstream intron and lead to increased splicing. In order to ensure that the increase in splicing
was not because of the lack of sequence upstream, I replaced the upstream sequence with
heterologous sequence. Figure 4.2 shows that the alt60/DSE also yields an increase in splicing
over the WT USE60/DSE120 construct, confirming the USE60 as a repressive sequence.

The roles of the USE60 as a splicing repressor and DSE120 as a splicing activator are
corroborated by in vivo minigene results. LEF1-E6 is more included when the USE60 is replaced
and is more excluded when the DSE120 is replaced (Figure 4.3). Considering that the signal
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induced increase of binding of CELF2 is localized to the DSE120, the in vitro splicing results show
that the reason this increase in binding results in an increase in LEF1-E6 inclusion is because the
DSE120 is an activator of splicing. Since the USE60 is a splicing repressor, the effect of the USE60
dominates in unstimulated cells by the binding of CELF2 and upon stimulation this repression is
relieved by increased CELF2 binding to the DSE120.
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The differing roles that CELF2 plays upon binding to the USE60 versus the DSE120 is also
apparent when CELF2 is significantly knocked down in unstimulated and stimulated JSL1 cells.
Michael Mallory in the lab used a lenti-viral expression vector to cause very effective knockdown of
CELF2 in both US and S JSL1 cells. In unstimulated cells, knockdown of CELF2 caused an
increase in LEF1-E6 inclusion suggesting that CELF2 is functioning as a repressor in this condition.
In stimulated cells, knockdown of CELF2 caused a decrease of LEF1-E6 inclusion suggesting that
CELF2 serves as an activator in this condition. This is in line with the current model, wherein the
effect of CELF2 binding the repressor USE60 is the dominant effect in unstimulated cells. Upon
stimulation the effect of CELF2 binding the activator DSE120 is the dominant effect (Figure 4.4)

It is possible that the activating nature of the DSE120 is not solely due to the increased
binding of CELF2 but due to some other protein interacting with the DSE120. In order to confirm
that CELF2 binding downstream of LEF1-E6 leads to increased inclusion I created 4 minigenes
that replaced the DSE120 with increasing amounts the high affinity SELEX sequences used in the
EMSAs (1x-4xUGUU). The EMSAs have shown that CELF2 binding increases from the 2xUGUU
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to the 4xUGUU sequences. Therefore, these constructs allow for precise control over how much
CELF2 can bind downstream. LEF1-E6 inclusion can then be monitored under unstimulated and
stimulated states (Figure 4.5).

In in vivo minigene assays, if the amount of CELF2 binding downstream correlates with
LEF1-6 inclusion, then inclusion should increase from the 1x to the 4xUGUU minigenes. If only a
precise amount of CELF2 binding is required for inclusion, then inclusion levels should spike for
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one of the UGUU minigenes and not the others. Finally, If CELF2 binding to the DSE120 is not the
sole cause for LEF1-E6 inclusion, then there should be no correlation between inclusion levels and
CELF2 binding. Figure 4.5 shows that increasing amounts of CELF2 binding downstream of LEF1E6 results in increasing amounts of LEF1-E6 inclusion. Therefore, the signal induced enhancement
of LEF1-E6 is solely due to the increase in CELF2 binding to the DSE120 downstream of exon 6.A
striking result from Figure 4.5 however is that the 1x-4xUGUU sequences do not recapitulate the
signal induced enhancement of exon 6 inclusion. The lack of signal responsiveness is not due to a
lack of sensitivity caused by too much inclusion because the 1-3XUGUU minigenes are comfortably
within the range to observe an increase. There is therefore something unique about the DSE120
in the context of LEF1-E6 that is capable of regulating the amount of CELF2 that binds to it
unstimulated cells versus stimulated cells.
In order to probe whether there was a difference in the way CELF2 interacts with the
USE60 and DSE120 in the unstimulated versus the stimulated state, I isolated protein from each
condition. The first step towards isolating US and S-CELF2 was to stably express FLAG-tagged
CELF2 in JSL1 cells. In order to obtain protein from both the unstimulated and stimulated
conditions, I grew 30L of FLAG-CELF2 expressing JSL1 cells, and stimulated 15L with PMA. After
72 hours, both the unstimulated and stimulated cells were harvested. Since CELF2 is
predominantly a nuclear protein39, nuclear extract was separated from the harvest and subjected
to a M2 FLAG affinity column to specifically pull out FLAG-tagged CELF2 (Figure 4.6).
To specifically probe how US and S-CELF2 interact with the USE60 and DSE120, I used
an Electro-Mobility Shift Assay (EMSA). For this assay, the USE60 and DSE120 were radiolabelled and then incubated with increasing amounts of US-CELF2 or S-CELF2. The incubation
allows RNA-protein complexes to form and then these radiolabeled RNA-protein complexes, are
visualized in a non-denaturing acrylamide gel using autoradiography (Figure 4.6). Figure 4.6 shows
that for the both the USE60 and DSE120, US-CELF binds in three distinct modes even at the
highest CELF2 concentration. By sharp contrast, S-CELF2 binds very co-operatively to both the
USE60 and DSE120, with the three species collapsing to one by the highest CELF2 concentration.
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The EMSAs were repeated 3 times and the results quantified showing the cooperativity present in
the binding of S-CELF2 to the RNA, that is absent from the US-CELF2 (Figure 4.6).
EMSAs were also repeated with US and S-CELF2 that was isolated in the presence of
DNase and RNase. The removal of nucleic acids provides for a cleaner pull-down and several
indirect associations that CELF2 made through RNA or DNA would be reduced (Figure 4.7). Figure
4.7 shows that the RNase treated US and S-CELF2 could not recapitulate the signal induced
change in interaction observed from the non-RNase treated protein. However, since the yield from
the pulldown was greatly improved, the EMSA was able to reach saturation and therefore apparent
Kds were calculated for these interactions. The binding of US and S-CELF2 to the USE60 and
DSE120 was compared to the high affinity CELF2 sequence 4xUGUU. Figure 4.7 shows that the
US-CELF2 and S-CELF2 in the presence of RNase are very potent binders of the USE60 and
DSE120 with a relative Kd of 15-20nM. This is a tighter interaction than the high affinity 4xUGUU
sequence which they bind with a relative Kd of 65nM (data not shown). The interaction of US and
S-CELF2 is non-cooperative and very similar to the binding of US-CELF2 in the absence of RNase
to these constructs.
Discussion:
CELF2 binding upstream of an alternative exon being repressive to inclusion and
downstream of an alternative exon being enhancing is a well-studied phenomenon in the
literature55,57–59,84. cTNT exon 555 and NMDAR1 exon 2158 have CELF2 regulatory elements
downstream that contribute towards greater inclusion. NMDAR1 exon 5 58, CFTR exon 957, Tau
exon 285 and CELF2’s own exon 6 all have CELF2 regulatory elements upstream that contribute
towards exon exclusion.
The literature therefore supports the model where CELF2 binding upstream is repressive
and downstream is enhancing. The in vitro splicing results and the 1x-4xUGUU minigene results
confirm that the DSE120 activates exon inclusion while the USE60 represses exon inclusion.
Combining this with what was learnt about the pattern of CELF2 binding in unstimulated and
stimulated cells, a clearer picture of the mechanism behind the enhancement of LEF1-E6 inclusion
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emerges. In unstimulated cells, the effects of CELF2 bound to the upstream repressor, USE60, are
dominant. Upon stimulation, this repression is relieved by a bolus of CELF2 binding downstream
to the activating DSE120. (Figure 4.3 panel C)
How is the binding of CELF2 so well regulated under these conditions? What is the
mechanism behind the preference for the USE60 in unstimulated cells, and DSE120 in stimulated
cells? One possibility is that there is an inherent difference in CELF2 itself between the two
conditions. Perhaps CELF2’s PTM landscape in unstimulated cells is inhibitory to binding the
DSE120. Upon stimulation this PTM landscape changes now promoting CELF2 binding to the
DSE120. A second possibility is that there are other splicing factors at play that actively keep
CELF2 from binding the DSE120 in unstimulated cells. Upon stimulation either a down-regulation
of this factor or the interference of another allows CELF2 to bind to the DSE120.
The EMSAs in the absence of RNase suggests that there is a difference in the way CELF2
pulldowns from US cells interact with the USE60 and DSE120 when compared to pulldowns from
stimulated cells. This difference in interaction can be attributed to either an inherent difference in
the CELF2 species between the two states or the presence of another splicing factor that was
pulled down with CELF2. The loss of differential binding upon Rnase addition suggests that there
was a factor present in the pulldown that lacked Rnase that was responsible for the change in
interaction. This doesn’t refute the necessity of a change in PTMs upon stimulation as it could be
how CELF2 regulates its binding with this other unknown regulatory protein. The next two chapters
of this thesis will discuss data that pertains to CELF2 PTMs in unstimulated and stimulated cells as
well the possible involvement of other regulatory proteins in the regulation of LEF1-E6.
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CHAPTER 5: POST-TRANSLATIONAL MODIFICATION OF CELF2 IN
UNSTIMULATED AND STIMULATED T CELLS
Introduction
As seen in Chapter 4, one possible mechanism for how CELF2 binding the DSE120
increases from unstimulated to stimulated T cells is by a change in a post-translational modification
(PTM). There are many examples of PTM’s on splicing factors that modulate their ability to regulate
splicing of their target exons. In some cases the modification directly affects the factors ability to
bind its target mRNA35,86–94. SPF45’s binding to fas exon 6 is regulated by 8 serine phosphorylations
that are N-terminal to its RRM. Mutation of these serines to alanines resulted in greater binding to
the fas substrate resulting in greater exon exclusion94. The kinase Chk1 phosphorylates serine 100
in RRM1 of the splicing factor HuR decreasing its affinity for the SIRT1 mRNA 91. Similarly, PRMT1
methylates PSF and enhances its interaction with mRNA86.
Modifications on splicing factors can also indirectly regulate splicing by regulating proteinprotein interactions. A well-studied example of this from the Lynch Lab is the phosphorylation of
PSF in unstimulated T cells. This modification causes it to be sequestered into a complex with the
protein TRAP150. Upon stimulation, GSK3 activity is downregulated, which therefore reduces PSF
phosphorylation. This leads to less PSF being sequestered by TRAP150, more being available to
bind to its target mRNA CD45, and regulate splicing35. SMAR1’s regulation of Sam68 is another
great example of PTMs indirectly regulating alternative splicing. Acetylated Sam68 is required for
the regulation of CD44 alternative exons. Smar1 in its unmodified state sequesters Sam68 into a
complex with a deacetylase. Phosphorylation of SMAR1 leads to a disruption of protein-protein
interaction with Sam68, allowing for the acetylation of Sam68 and its downstream regulation of
CD44 alternative splicing90. PTMs can also indirectly regulate splicing by affecting the localization
of splicing factors. The disruption of phosphorylation of SRSF1 by SRPK1 results in the
translocation of SRSF1 out of the nucleus and thus making it unavailable to its target mRNA Rac1b
exon392.
There is significant evidence in the literature that shows how PTMs can affect the function
of the CELF family of proteins. CELF1 has two phosphorylations with described consequences in
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the literature. In myoblasts, Ser28 of CELF1 can be phosphorylated by Akt which increases its
interaction with Cyclin D1 mRNA95. Ser302 phosphorylation with cyclinD3 has also been shown to
have effects on both CELF1’s interaction with C/EBPβ mRNAs as well as the protein p21 95. In the
context of T cells, CELF1 is phosphorylated upon T cell activation which decreases its ability to
bind GRE-containing mRNAs96.

There is one well described instance of a PTM regulating CELF2 function. In rat smooth
muscle cells, phosphorylation of Tyr39 in RRM1 of CELF2 by C-SRC tyrosine kinase enhances its
interaction with COX2/PTGS2 mRNA97. The interaction stabilizes the mRNA preventing decay and
is not a splicing regulatory event. However, it highlights the possibility of how PTMs on CELF2 can
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modulate RNA binding. The only other modification that has been identified on CELF2 is the
acetylation of Lys44089,98. It lies in RRM3 of CELF2 and therefore could have a role in modulating
RNA binding as well (Figure 5.1).
In order to better map CELF2’s PTM landscape and ascertain whether T cell activation
causes any changes in this landscape, I collaborated with the Wistar Institute’s mass spectrometry
core and used mass spectrometry to capture a global a view of CELF2’s PTMs in the unstimulated
and stimulated state.
Results:
In order to investigate whether CELF2 had any significant changes in its PTM landscape
upon stimulation, I used the FLAG-CELF2 protein isolated from US and S JSL1 cells according to
the protocol outlined in Figure 4.7 panel A. Additionally, the purification was done in the presence
of phosphatase and de-acetylase inhibitors in order to preserve as many of the native PTMs as
possible (Figure 4.7 panel A)
This protein was snap frozen and sent to the Mass spectrometry core at the Wistar Institute
for further processing and analysis. At the institute, since the purification contained a significant
portion of contaminating proteins (Figure 4.7), SDS-PAGE was performed and the band
corresponding to CELF2 was specifically excised. This band was then subjected to three different
proteolysis conditions to increase our chances of getting the best peptide coverage of the protein.
The three conditions were complete Trypsin digest, partial trypsin digest and Chymo-trypsin
digest.

The resulting peptides were analyzed on their mass spectrometer. LC-MSMS was

performed which collected both primary collision information (MS1) as well as secondary collision
information(MSMS or MS2) in order to detect peptides with masses corresponding to any added
PTMs (Figure 5.2, panel A). The institute mapped the peptides to CELF2’s protein sequence and
annotated any PTMs that were found.
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Figure 5.2 shows the peptides that were recovered from the mass spectrometry
analyses of each digest condition, mapped against a schematic of the protein. As you can see, all
three conditions provided great coverage of the three RRMs. The chymo-trypsin digest was the
only condition that provided any peptides in the linker region of the protein, however there were no
PTMs identified amongst them.
Analysis of the number of modified peptides compared to unmodified peptides in a small section of
the N-terminus of US-CELF2 revealed that only a small percentage of the peptides have the
modification (Figure 5.3). When I analyzed all the sites where PTMs were present, I found that to
be the case in all instances. This suggests that only a small percentage of CELF2 was posttranslationally modified. I did not consider deamidations or oxidations in this analysis. In order to
isolate whether the small number of modified peptides was an accurate representation of the
purified FLAG-CELF2 or a consequential loss in the mass spectrometer, I performed 2D gel
electrophoresis on the purified unstimulated and stimulated protein. This procedure is used for the
identification of the pH distribution of species of the same molecular weight. A protein without many
PTMs will run close to its pI while modifications tend to cause a shift to a more acidic pH.
CELF2 has a pI of 8.6 and so any modified version of CELF2 would be expected to run at
a more acidic pH. The 2-D gels were probed via western blot with anti-Flag and anti-CELF2
antibody to get a specific pH profile for CELF2. Figure 5.3 shows that the majority of the CELF2
protein runs ~8.5, which is close to the protein’s pI. However, there is a small population of modified
protein that runs at ~pH 2-3, very akin to the mass spectrometry results. As a control for the FLAGCELF2 gel I also ran unstimulated and stimulated nuclear extract to check whether the purified
protein was representative of the protein extracted from the cell. This also ensures that there
weren’t any drastic changes that resulted in a loss of PTMs during the FLAG purification process.
As shown in Figure 5.3, CELF2 in nuclear extract also runs mostly around pH 8.6 with a small
population running at a lower pH (Figure 5.3).
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This data confirmed that the mass spectrometry results were an accurate representation
of the source material being provided. Focusing in on the small percentage of peptides that were
modified, I mapped out where the modifications were on the protein (Figure 5.4). The modifications
mostly lie in the RRMs with 5 on RRM1, 5 on RRM2 and 3 on RRM3. There was also 1 in the Nterminus of the protein and 1 in the sequence connecting RRM1 and RRM2. There were no PTMs
found in the linker domain but this most likely because of the low peptide of coverage in this region
(Figure 5.4).

Since we were interested in changes in PTMs, I compared the intensity of the MS peptide
peaks for identified PTMs in unstimulated and stimulated cells (Data from the Wistar institute). The
intensity of the peaks can tell us whether there is more or less of that particular modification in each
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condition. The modifications that had detectable MS1 peaks in both conditions were used for this
analysis. I did not consider peaks that were completely absent in one condition versus the other as
the reason for the absence is most likely due to a difficulty in detection in the mass spectrometer
and not a physiological reality.
The fold change in intensities between US and S peaks was calculated by dividing the
unstimulated peak area (Area (US)) by the stimulated peak area (Area (S)). Figure 5.4 panel C
shows there were no significant changes in the intensity of the MS peaks between the two
conditions.
Discussion:
Post-translational modifications on splicing factors can play a crucial part in the regulation
of alternative splicing. In order to determine whether PTMs are important the function of CELF2, I
collaborated with the Wistar Institute and used mass spectrometry to probe CELF2 PTM landscape
in US and S cells. The small size of the population of modified peptides was a surprising find. It
could indicate that CELF2 is not largely regulated via its PTMs in JSL1 cells. It is important to keep
in mind that there could be a loss of PTMs after harvesting the cells.

Since the 2D gel

electrophoresis profile of unstimulated and stimulated nuclear extract looked very similar to the
purified protein, if there was any loss of PTMs it was happening during the isolation of nuclear
extract (Figure 5.3). However, the nuclear extract used for the 2D gel analysis is splicing competent
and was used to recapitulate LEF1-E6 regulation in in vitro splicing experiments. This suggests
that although less efficient, the levels of CELF2 and CELF2 PTMs are sufficient for splicing
regulation. The small population size of modified CELF2 does not negate the possibility of PTMs
being important for the regulation of LEF1-E6. There could be a mechanism by which the modified
CELF2 binds to the USE60 and DSE120, either because of a greater affinity for these sequences
that the unmodified protein or via interaction with other splicing factors.
Of the PTMs that were identified, 83% of them were newly annotated modifications, not
mentioned in the literature to date. We were also able to pick up the two annotated modifications
in our experiments adding more credence to our data. The number of modifications in the RRMs is
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not surprising as most of the annotated and studied examples of PTM in splicing lie in the RRMs.
In depth analysis of the RRM’s PTMs however showed that there is no real change in their level
upon T cell stimulation. The largest change observed is on S8 at a fold change of 3.2 (Figure 5.4).
The lack of dramatic change in CELF2’s PTMSs suggests that its preferential binding of the USE60
in unstimulated cells and DSE120 in stimulated cells is not caused by regulating PTMs on its RRMs.
An unfortunate drawback of this experiment is the lack of information in the linker domain
of CELF2 that connects RRM2 and 3. A study by Singh et al showed that the linker domain is very
important to CELF2’s role as a regulator of splicing. The authors show that CELF2 is capable of
activating exon inclusion via either RRM1 & RRM2 or via RRM3. However the caveat to both modes
of regulation is that part of the linker domain is required – 70 residues adjacent to RRM1 & 2 and
the 119 residues adjacent to RRM3. This suggests that this region is an important part CELF2’s
function as a regulator of splicing99. The linker domain has large segments that are rich in serines
and threonines making them prime candidates for PTMs. Optimizing a proteolytic regime that
allows for effective analysis of the linker region could shed light on why this region has been shown
to be indispensable for CELF2 function as a splicing factor.
These experiments have shown that most of the CELF2 in JSL1 nuclear extract is
unmodified. Of the small population that is modified, I discovered 12 previously undescribed PTMs
on CELF2’s RRMs with the help of the Wistar Institute’s mass spectrometry core. This can be a
guide for future structural and functional studies of CELF2. However, with the lack of information
for the linker domain of CELF2, a definitive statement on whether there is a change in CELF2s
PTM landscape cannot be made. Further efforts to study the PTMs of the linker domain will need
to be made before this hypothesis is declared to not contribute to regulation of LEF1-E6.
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CHAPTER 6: COMBINATORIAL CONTROL OF LEF1-E6 ALTERNATIVE
SPLICING
Introduction:
Recent global studies of alternative splicing that probe the binding sites of splicing factors
(called CLIP-seq or Cross Linking Immuno-Precipitation) are revealing an immense amount of
overlap between various splicing factors and the alternative exons they bind around. A study that
highlights this phenomenon was done by Huelga et al where they performed CLIP-seq on several
hnRNP proteins (A1, A2/B1, F, M and U) and found that the majority alternative exons regulated
by hnRNPs are regulated by 2 or more of the tested proteins. A similar study performed with the
protein PTB and Quaking have shown that 25% of the exons regulated during myogenesis are
under the control of both these proteins100. These global studies correlate with studies of individual
splicing events, whose alternative exons are almost always are under the influence of multiple
splicing factors.
One of the best examples of combinatorial splicing control comes from CD45 exon4, an
alternative exon studied by the Lynch Lab. Here, exon 4 is repressed upon T cell stimulation and
this repression is due to a ESS in exon 4 titled, quite simply, ESS134. The lab has gone on to show
that hnRNPL binds to this exon and causes repression by recruiting hnRNPA1 and together
“holding” U1snRNP in conformation that makes spliceosome assembly more difficult 17,101. This
exon also relies on two other proteins, hnRNPLL and PSF that can enhance this repression upon
T cell stimulation33,35,74,102.
Other examples include the regulation of α-tropomyosin exon 2 by the splicing factors 9G8
and hnRNP F/H103, DMD exon 39 by hnRNPA1, hnRNP A2/B1 and FUBP1104, β-tropomyosin exon
6B by hnRNPA1, SC35 and ASF/SF2, FGFR1 exon IIIc by hnRNPF/H and Fox2 105 and HIV tevspecific exon 6D by SC35 and hnRNP H106 to name a few. The CELF family of proteins can also
regulate splicing in collaboration with other factors. The most prevalent family that collaborates with
CELF is the MBNL family of factors. Together they have been shown to regulate cTNT exon 5, IR
exon 11 and CLCN1 exon 7a107,108. More globally, these two families have been shown have
antagonistic effects on exon fate in the developing skeletal and heart muscle 109. CELF2 more
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specifically also collaborates with PTB as in the case of cTNT exon 555 and α-actinin’s NM and SM
exons59.
However there is less data on how CELF2 regulates signal induced alternative splicing and
what other factors, if any, collaborate with CELF2 in a signal induced fashion. I have established
so far that CELF2 represses exon 6 inclusion in unstimulated cells by predominantly binding
upstream of the alternative exon. Upon T cell stimulation, CELF2 activates exon 6 inclusion by
predominantly binding downstream of the alternative exon. Considering CELF2 ability to
collaborate with other splicing factors, it is possible that where CELF2 binds around LEF1-E6 is
regulated by a yet to be determined splicing factor. In order to identify the proteins that bind around
LEF1-E6, I UV cross-linked radiolabeled USE60-exon6-DSE120 (WT) in US and S nuclear extract.
Some of the bound proteins were identified by immunoprecipitation and their involvement in the
signal induced enhancement of LEF1-E6 was assessed by knock down of the protein in JSL1 cells
and monitoring levels of exon 6 inclusion.
Results:
UV crosslinking of proteins to radiolabeled RNA is a very powerful tool by which to narrow
down which splicing factors bind around a region of interest. In this case, radiolabeled USE60exon6-DCE-DSE120 RNA was incubated in US and S nuclear extract to allow proteins to bind. The
RNA was then digested and the proteins analyzed on a SDS-PAGE gel. Proteins that were directly
bound to the radiolabeled substrate appear upon phospho-imaging by virtue of being covalently
linked to radio-labeled nucleotides. Figure 6.1 shows, 7 proteins, including CELF2 bind in and
around LEF-E6 (figure 6.1 panel A).
In order to hone in on the proteins that just bind to the USE60 and DSE120, I performed
the same assay with several deletion mutants of USE60-exon6-DCE-DSE120 (WT). The construct
that replaces the exon with heterologous sequence, USE60-het-DCE-DSE120 (∆exon), didn’t
significantly change the binding pattern as compared to WT (Figure 6.1, panel B and C). Basal
levels of CELF2 binding increase however suggesting that the exon harboured a splicing repressor.
Signal induced increase of CELF2 however is unaffected. Upon replacement of the DCS in the
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USE60-het-het-DSE120 construct (∆DCS), we see a further increase in basal levels of CELF2
suggesting that the DCS also contained a basal splicing repressor while keeping signal induced
increase in CELF2 binding intact (Figure 6.1, panel B and C).
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In order to discover any protein that specifically bound to the DSE120 or the USE60, I also
performed the UV crosslinking with USE60-exon6-DCE-het (alt120), het-exon6-DCE-DSE120
(alt60) and het-exon6-DCE-het (alt both). In the alt120 substrate (Figure 6.1, panel D), the binding
of p100 is lost, suggesting that that protein binds specifically to the DSE120. p25, also increases
upon replacement of the DSE120, suggesting there is element within that sequence that is
inhibitory to p25 binding. Additionally, there is an extra protein that binds around 60 kDa. It is very
possible that the heterologous sequence used to replace the DSE120 has binding sites of its own,
which would explain the extra bands. However, as discussed in Chapter 3, the biggest change in
the alt120 construct is the lack of increase in CELF2 binding upon stimulation.
The alt60 construct sees little to no change in any bound proteins highlighting the
importance of the DSE120 in this regulation. Whereas, the alt both substrate looks almost identical
to the alt120 substrate, also highlighting that most of the change that occur in binding occurs at the
DSE120. One thing to note is that many of these protein bind substrate irrespective of what
elements are replaced. It is most likely that these proteins are part of the spliceosomal machinery
that are recruited to a functional 5’ and 3’ ss irrespective of the regulatory elements present.
Besides p150, all the other proteins show sensitivity to stimulation and/or replacement of the
USE60 or DSE120 and are potentially involved in the enhancement of exon 6 inclusion upon signal
induction (Figure 6.1, panel D). I had previously confirmed that the 50kDa band was indeed CELF2
by IP with a CELF2 antibody. I have identified two more proteins, hnRNPH1 and hnRNP C, which
bind around LEF1-E6.
Since the protein band that has the greatest change in binding around LEF1-E6 between
unstimulated and stimulated nuclear extract is the one around 50kDa (Figure 6.1), I wanted to
ensure that there weren’t other proteins besides CELF2 that were contributing to the change. The
best candidates that might overlap with CELF2 at 50 kDa are the hnRNP F/H family of proteins.
This family consists of hnRNPH1, H2, H3 and hnRNP F. hnRNP H1 and H2 are the best
characterized of the H proteins and are 96% identical. hnRNP F is 68% identical to hnRNPH1 but
with 80% similarity in the region of RRM3105. These proteins are similar to CELF2 in that they also
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contain 3 RRM domains with a linker domain connecting RRM2 and 3. They differ in that they have
an additional glycine-rich domain at their C terminus. They are also similar to CELF2 in that their
molecular weight is ~50kDa and therefore overlap with CELF2 on SDS-PAGE.
In order to determine if any members of the hnRNP F/H family bound the region around
LEF1-E6, I used an antibody that recognized both hnRNP F and H. As shown in Figure 6.2 panel
A, a band around 50kDa specifically precipitated with this antibody. In order to determine whether
the band corresponded to the F or H proteins, I used a H family specific and a F specific antibody
in the IP. Figure 6.2 panel A shows that the H antibody specifically pulled down the 50kDa band as
opposed to the F antibody. I could therefore confirm that hnRNP H does bind around LEF1-E6. I
also wanted to test whether hnRNP H binding changed upon stimulation or whether the change in
binding seen in Figure 6.1 was purely due to CELF2. hnRNP H pulled down to approximately the
same amounts in both US and S nuclear extract, confirming that the increase in binding was only
due to CELF2 (Figure 6.2, panel A). In order to isolate whether H binds the USE60 or DSE120, I
performed the IP with the alt60, alt120 and alt both substrates (Figure 6.2, panels B and C). Figure
6.2 panel C shows there is a slight decrease of binding in the alt60 construct, suggesting that the
USE60 could be its preferred binding site. However, since the protein still binds in the alt both
substrate, it seems that hnRNP H is capable of binding to a few sites around the exon
Although H binding doesn’t change drastically upon stimulation, it is possible that its mode
of binding changes such that it forms different interactions upon stimulation that allow for increased
CELF2 binding to the DSE120. In order to determine whether hnRNP H played a role in signal
induced enhancement of LEF1-E6 inclusion, Nicole Martinez in our lab knocked down this protein
in US and S JSL1 cells. Analysis of LEF1-E6 inclusion showed that knockdown of H in US cells
caused a small decrease in LEF1-E6 inclusion. In stimulated JSL1’s knockdown of H had no effect
on exon 6 inclusion (Figure 6.2 panel D). This implies the H serves as a modest activator of LEF1E6 inclusion in US JSL1 cells. This however does not provide an explanation for how CELF2
binding is regulated at the DSE120 in US cells. If H played a part in restricting CELF2 binding to
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the DSE120 in US cells, its knockdown should increase LEF1-E6 inclusion in this condition.
Therefore, we can confirm that hnRNP H mildly contributes to the amount inclusion in US T cells
but does not affect signal induced enhancement of LEF1-E6.
Another protein band who’s binding changes upon stimulation is p37 which decrease upon
stimulation as CELF2 binding levels increase. A prime candidate for this species is hnRNP C, a
member of the hnRNP family of splicing factors with catalogued roles in mRNA splicing 110,111. UV
crosslinking the IP with an anti-hnRNP C antibody and radio-labeled WT, show a specific interaction
between the two, confirming that hnRNPC binds in the LEF1-E6 region. Upon stimulation as CELF2
binding levels increase, hnRNPC levels decrease. This pattern is maintained in the alt60 substrate
where there is also an increase in CELF2 upon stimulation and a corresponding decrease in hnRNP
C. In the alt120 however, CELF2 binding is minimal and with the absence of the DSE120, there is
no change in CELF2 levels upon stimulation. Figure 6.3 panel A shows that hnRNP C levels also
remain unchanged in the alt120 substrate upon stimulation.
An important question to consider is whether the decrease in hnRNP C binding (with a
concurrent increase of CELF2 binding to the DSE120) only possible in the stimulated state or can
an increase of CELF2 binding to the DSE120 in the unstimulated state also elicit the same response
from hnRNP C. Since both the ∆exon and the ∆DCS exhibit a greater amount of CELF2 binding to
the DSE120 in the unstimulated state as compared to WT, I tested the IP of hnRNP C in these two
substrates. In both the ∆exon and ∆DCS, the binding of hnRNP C in the unstimulated extract was
significantly lower than in the WT substrate and reduced further upon stimulation (Figure 6.3, panel
B). Therefore, the correlation between CELF2 and hnRNP C binding is not dependent on the state
of the extract and only dependent on the amount of CELF2 bound to the DSE120.
To investigate whether a reduction in CELF2 can lead to increased binding of hnRNP C on
the RNA, I repeated the UV crosslinking with the ∆DCS construct in extracts immuno-depleted of
CELF2 and C (depletion done by Laura Agosto and Sam Allon respectively). When levels of CELF2
are reduced via immune-depletion, there is an almost complete loss of all protein binding, including
hnRNP C, on the RNA. However, if levels of hnRNP C are also reduced via immune-depletion,
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there is only a minimal effect on CELF2 binding (Figure 6.3 panel C). The fact that hnRNP C binding
on the RNA is dependent on the presence of CELF2 suggests that CELF2 recruits hnRNP C to the
RNA. This hypothesis is supported by the fact the upon hnRNP C depletion, CELF2 binding is
largely unaffected (figure 6.3, panel C). This is in stark contrast to the behavior or CELF2 and
hnRNP C in the region around MKK7 exon 2 (MKK&-E2), an alternatively spliced exon studied by
Nicole Martinez in the lab. In the case of MKK7-E2, CELF2 and hnRNP C compete for binding as
depletion of CELF2 leads to an increase in hnRNP C binding and vice versa (Figure 6.3, panel D).
To determine the effect hnRNP C has on signal induced enhancement of LEF1-E6, I used
RNA from hnRNP C knockdowns in unstimulated and stimulated JSL1s (from Nicole Martinez in
the lab) to probe the inclusion of LEF1-E6 via RT-PCR. LEF1-E6 inclusion is repressed in both
cases suggesting that hnRNP C functions as an activator of LEF1-E6 splicing in both unstimulated
and stimulated cells (Figure 6.3 panel E and F). A double knockdown of CELF2 and hnRNP C was
done but the data was variable and inconclusive. This could be due to off target effects caused by
the double knockdown.
I also performed UV crosslinking IPs on MBNL1, MBNL 2, PSF, HuR, Fox2 and hnRNP L,
none of which were found to interact LEF1-E6 constructs.
Discussion:
The inclusion of LEF1-E6 in unstimulated and stimulated T cells is determined by the
regulation of CELF2 binding to a repressive sequence (USE60) upstream of the exon and an
activating sequence (DSE120) downstream of the exon. In unstimulated cells, CELF2 binding is
biased towards the repressive USE60 while in stimulated cells, CELF2 binding is biased towards
the activating DSE120. A possible mechanism for how CELF2 binding is regulated is by the
involvement of a second protein that inhibits CELF2 binding downstream in the unstimulated state
and this inhibition is relieved upon stimulation.
Seven proteins, including CELF2, bind LEF1 around the region of exon 6 (Figure 6.1). One
of these proteins is hnRNP H, a splicing factor with a history of influencing alternative
splicing105,106,112–114. hnRNP H has a very minimal effect on signal induced enhancement of LEF1
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exon 6 inclusion as knockdown studies show it has a mild effect activating effect in unstimulated
cells (Figure 6.2). This mild activation in unstimulated does not explain how CELF2 binding is
restricted to the USE60 in this state. If H1 played a part in restricting CELF2 binding to the DSE120
in US cells, its knockdown should increase LEF1-E6 inclusion in this condition. Therefore, we can
confirm that the hnRNP H family of proteins mildly contributes to the amount inclusion in US T cells
but does not affect signal induced enhancement of LEF1-E6.
The other protein identified was p37 which was found to be hnRNP C. UV crosslinking of
WT substrate in unstimulated nuclear extract shows that the levels of hnRNP C and CELF2 are
relatively similar. However, upon stimulation, as CELF2 binding increases on the DSE120, hnRNP
C binding decreases. Additionally, the decrease in hnRNP C binding is dependent on the increase
of CELF2 binding to the DSE120 as is apparent when the DSE120 is replaced in the USE60-exon6DCE-het substrate. Here, the lack of the DSE120 prevents an increase of CELF2 binding upon
stimulation which also results in a lack of decrease in hnRNP C binding. This suggests that the
reduction in hnRNP C binding is not what causes the concurrent increase in CELF2 binding to the
DSE120 but the converse wherein hnRNP C is removed from the RNA by the increase in CELF2
binding to the DSE120 upon stimulation. Immuno-depletion of CELF2 shows that hnRNP C requires
the binding of CELF2 to the USE60 or DSE120 in order to interact with the RNA. The converse is
not true as the immuno-depletion of hnRNP C has a negligible effect on CELF2 binding (Figure
6.3).
One explanation for the requirement of CELF2 in hnRNP C’s interaction with the RNA is
that CELF2 forms a complex with hnRNPC and recruits it to the region around LEF1-E6. In
unstimulated cells this CELF2-hnRNP C complex binds to the USE60. Upon stimulation, the
increase of CELF2 binding downstream interferes with the upstream CELF2-hnRNPC interaction
and releases hnRNP C from the transcript. It is important to note that hnRNP C is capable of binding
the DSE120 in the absence of the USE60 (Figure 6.3 panel A) and that the decrease in binding
due to CELF2 is independent of which elements it is bound to. This however does not explain the
mechanism behind how CELF2 is biased towards the USE60 in unstimulated cells and what causes
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the increase in binding to the DSE120 upon stimulation. The knockdown of hnRNP C shows that it
is an activator of LEF1 splicing in both unstimulated and stimulated cells. If the presence of hnRNP
C in unstimulated cells was responsible for the lack of CELF2 binding downstream, then it would
serve as a repressor in unstimulated cells (Figure 6.3).
The dependence of hnRNP C binding on the presence of CELF2 is still very interesting to
study as it highlights the various ways in which splicing factors co-operate or antagonize to interact
with RNA. The one way dependence of hnRNP C on CELF2 in the case of LEF1 is particularly
interesting considering data from Nicole Martinez in my lab, which shows that in the region around
MKK7-E2, CELF2 and hnRNP C compete for binding. Depletion of CELF2 leads to an increase in
hnRNP C binding and vice versa. It would be very interesting to determine the specific conditions
that cause competition versus dependency (Figure 6.3 panel D).
Although hnRNP H and C bind to the region around LEF1-E6 neither is involved in the
signal dependent enhancement of LEF1-E6 inclusion upon stimulation. Identification of p45, a
protein whose binding also decreases upon increase CELF2 binding upon stimulation could help
decipher this mechanism. Additionally, p100 could especially be important as its levels decrease
upon stimulation and upon loss of DSE120. Considering it is likely p100 binds to the DSE120
(Figure 6.1 panel D), it could sterically block CELF2 from binding part of the DSE120 in
unstimulated cells and this effect is reduced upon stimulation perhaps due to the down regulation
of expression of this protein. Nonetheless, further studies into the identification of these proteins
could shed light on the mechanism behind the signal induced enhancement of LEF1-E6 in T cells.
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CHAPTER 7: CONCLUSIONS AND FUTURE DIRECTIONS
The region encoded by LEF1-E6 is crucial to the upregulation of T cell receptor  and is therefore
preferentially included in the final LEF1 pre-mRNA transcript upon T cell stimulation. Previous work
by Mallory et al identified two intronic cis-elements, the USE60 and DSE120, flank exon 6 and are
required for this preferential inclusion upon stimulation. Mallory et al also discovered that the
splicing factor CELF2 bound these two regulatory elements and the increase of CELF2 binding to
these elements upon stimulation led to increased exon 6 inclusion
In Chapter 2 of my thesis I show that the USE60 and the DSE120 are required but also
sufficient for enhancement of exon inclusion upon stimulation. Establishing the minimal sequence
elements required for exon enhancement is crucial to accurately describing a mechanistic model
for how exon 6 of LEF1 is preferentially included upon T cell stimulation. In Chapter 3 and Chapter
4, I correlate the binding of CELF2 to the function of the USE60 and DSE120. I show that the
USE60 and DSE120 do not work synergistically to enhance inclusion but function antagonistic to
each other. The USE60 is a repressor of splicing while the DSE120 is an enhancer. Consequently,
I show that in order to achieve an increase in exon 6 inclusion only upon stimulation, CELF2 binding
is highly regulated between the USE60 and DSE120. In unstimulated cells, binding is biased
towards the USE60 and upon stimulation the increase in CELF2 binding happens purely on the
DSE120, the splicing activator. This bolus of CELF2 binding on the DSE120 upon stimulation leads
to an increase in exon 6 inclusion.
A more accurate analysis of this data is that in unstimulated cells, CELF2 binding on the
DSE120 is inhibited, allowing the USE60 to have the dominant effect. Upon stimulation this
inhibition is relieved, allowing more CELF2 binding to the DSE120, which overcomes the repressive
effects of the USE60. This inhibition of CELF2 binding to the DSE120 in unstimulated cells is a key
point of regulation in this system. In vivo mingene data combined with UV crosslinking data shows
that both the exon and DCS regulate CELF2 binding to the DSE120 in unstimulated cells.
The minigene studies of the exon and DCS show an increase in Exon 6 inclusion over
WT in unstimulated cells. The UV crosslinking profiles of these constructs in unstimulated nuclear
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extracts shows an increase in CELF2 binding as well. This suggests that some of the inhibition of
CELF2 binding the DSE120 in unstimulated cells was relieved by the replacement of these
sequences. However, both the exon and DCS constructs are still capable of a further increase
of CELF2 binding on the DSE120 and therefore a further increase in exon 6 inclusion upon
stimulation (Figure 6.1). Therefore, the signal responsive sequence that is responsible for inhibiting
CELF2 binding to the DSE120 in unstimulated cell is contained within the DSE120. Creating
minigenes that systematically replace/delete parts of the DSE120 using the DCS as the template
would isolate the specific part of the DSE120 that contributes to inhibiting CELF2 binding in
unstimulated cells.
Having the sole point of regulation revolve around binding of CELF2 to the DSE120
however implies that no other sequence element would be required. In fact UV crosslinking analysis
of the USE60 shows that the increase of CELF2 binding to the DSE120 upon stimulation can still
take place in the absence of the USE60. However, the minigene studies confirm that the USE60 is
required for the signal induced enhancement of exon 6 inclusion. In the USE60 minigene, despite
the increase of binding on the DSE120 upon stimulation, there was no further increase in exon
inclusion. The absence of the USE60 does increase basal levels of inclusion to 80% as it is a
splicing repressor. This does not explain why there is no further increase upon inclusion because
the exon minigene also has a basal level of inclusion of 80% and is still capable of further increase
in inclusion. Therefore, the regulation of CELF2 binding to the DSE120 is independent of the
USE60. However, the mechanism by which it increases exon 6 inclusion is through the USE60. In
other words, the increase of CELF2 binding to the DSE120 activates exon 6 inclusion by derepressing the repression of the USE60.
This data leads to a model where binding of CELF2 to the DSE120 is inhibited in
unstimulated cells and this inhibition is relieved upon stimulation. Once CELF2 is allowed to bind
to DSE120 is doesn’t function independently to overcome the effects of the USE60 but rather
“activates” exon 6 inclusion by de-repressing the repression caused by the USE60. Therefore,
when the USE60 is absent (as in the USE60 minigene construct), the increase in CELF2 binding
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to the DSE120 has no effect on inclusion as the target on which it acts is absent. To test this
hypothesis in the future, the 1X-4X minigene constructs can be used. These minigenes are a
convenient way to titrate the amount of CELF2 that binds downstream. In the presence of the
USE60, each increase in high affinity binding sites and therefore each increase in CELF2 binding
led to an increase in exon 6 inclusion. Replacing USE60 in these minigenes, can test whether the
mechanism by which the increase in CELF2 binding downstream leads to increased exon inclusion,
occurs through the USE60. If the activation of exon inclusion is through the de-repression of the
USE60, there should be no increase in inclusion in any of the 1-4xUGUU minigenes.

In Chapter 5, I describe my efforts to determine whether the regulation of CELF2 binding
to the DSE120 in unstimulated and stimulated cells is due to a change in its PTM landscape. In
collaboration with the Wistar Institute’s mass spectrometry core, we performed mass spectrometry
studies of CELF2’s PTM landscape and revealed 12 previously unannotated PTMs on CELF2
RRMs. None of these PTMs appeared to change after stimulation and therefore couldn’t explain
the differential binding of CELF2 on the DSE120. However, the linker domain escaped analysis
under the current digest conditions. This domain has been shown to be crucial for the regulation of

66

alternative splicing by CELF2’s RRMs115. It is possible that a PTM in the linker domain could be
regulating CELF2 ‘s interaction with RNA.
Evidence from Han et al has shown that CELF2 can regulate alternative splicing via either
RRM1+RRM2 in tandem, or via RRM3115. The differential binding in unstimulated and stimulated
cells could be due to the requirement for one set of RRMs versus the other. For future studies, the
bacterial expression system for his-CELF2 can be used to create domain deletions of CELF2.
These can be tested in EMSA to see if either set of RRMs has a particularly low affinity for the
DSE120. These can also be used in in vitro splicing assays to test whether one set of RRMs is
more efficient at activating splicing over the other. The EMSAs I have done with both his-CELF2
and the modified FLAG-CELF2 have shown that the PTM are not required for RNA interaction, and
therefore determining whether there is a bias in RRM use for the DSE120 could shed some light
on the mechanism by which CELF2 binding to the DSE120 is regulated.
Chapter 6 details my efforts into identifying other proteins that could also be playing a part
in how LEF1-E6 is regulated. These proteins could interact with CELF2 differentially between
resting and stimulated cells and thereby regulate when it binds the DSE120. These proteins could
also interact with DSE120 differentially between unstimulated and stimulated cells and sterically
hinder binding of DCSE120. I have identified two proteins, hnRNP H and hnRNP C, that bind
around the region of LEF1-E6. However, there are a few other candidates that have yet to be
identified. From the UV crosslinking of LEF1-E6 substrates in nuclear extract (Figure 6.1), p45 and
p100 stand out as being the most sensitive to PMA stimulation and DSE120 replacement.
Identification of these proteins via UV crosslinking IP should be pursued to assess their involvement
in enhancement of LEF1-E6 upon signal induction.
Finally, the end result of the regulation of CELF2 binding is the manipulation of spliceosome
assembly to either promote or inhibit exon inclusion. Initial results probing spliceosome involvement
have shown that increasing splice site strength does not affect signal induced regulation suggesting
that spliceosome assembly is unaffected at the point of splice site recognition. This is corroborated
by preliminary results monitoring spliceosome assembly in WT and DSE120 constructs. In both
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cases, the formation of A complex (where splice site recognition takes place) was unhindered, even
with the replacement of the DSE120. Future studies should include using the in vitro splicing
conditions described in this thesis to optimize spliceosome assembly reactions to identify which
stage in spliceosome assembly is being inhibited in the unstimulated state. Being able to determine
the exact point in spliceosome assembly that is being affected by the lack of CELF2 binding
downstream would provide valuable information behind the mechanisms of alternative splicing
regulation by CELF2. Furthermore, the in vitro splicing reactions can be used to purify assembled
spliceosomes from stimulated and unstimulated state to identify what specific interactions with the
spliceosome are important to LEF1-E6 regulation.
Studies that have investigated CELF2’s interactions with spliceosome components during
alternative splicing regulation suggest that CELF2 activates exon inclusion by binding downstream
of an alternative exon and stabilizing the association of U2 snRNP upstream 56. Additionally, CELF2
represses exon inclusion by binding upstream of an alternative exon and displacing the association
of U2AF6557. It is possible that these mechanism are at play in LEF1-E6 regulation. The current
model states that CELF2 binding DSE120 encourages exon 6 inclusion by de-repressing the
repressive effect of the USE60. The binding of U2AF65 at the PPT is crucial to U2 snRNP’s
association at the 3’ss and further assembly of the spliceosome. If the CELF2 that binds the USE60
inhibited or destabilized U2AF 65 binding, this would also effect binding of U2 snRNP and reduce
exon 6 inclusion. Upon stimulation, greater CELF2 binding downstream to the DSE120 would
stabilize U2 snRNP at the upstream 3’ss and therefore encourage exon inclusion. This would also
explain the requirement of both the USE60 and DSE120. In the absence of the USE60, there would
be no destabilization of U2AF65 and therefore no requirement for stabilization of U2snRNP.
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CHAPTER 8: MATERIALS AND METHODS
Minigenes and RNA
The 90/160, 0/160, 90/40, alt120 and Δexon minigenes were previously described in
Mallory et al, 2011. Briefly, the minigenes consist of LEF1 exon 6 and surrounding intron flanked
by intron and exon sequence from the human β–globin gene. alt-both was made using PCR by
using the alt60 and alt120 sequences to replace the USE60 and DSE120 in the same construct.
ΔDCS was made using PCR with primers to the DCS element Δexon and replacing it with____.
The lab has used this sequence extensively in previous studies with no discernable effects on
splicing. 1x-4x UGUU minigenes were made using synthetic oligos for the 1xUGUU sequences and
with added restriction enzyme sites to allow oligomerization. These were cloned into the WT
minigene to replace the DSE120.
Oligonucleotides encoding the USE60 and DSE120 were cloned directly downstream of a
T7 polymerase promoter and served as templates for in vitro transcription. 1x-4x UGUU were
amplified from minigenes with primers with a T7 tag attached using PCR and used as templets for
in vitro transcription. The RNAs were transcribed with T7 polymerase (Promega) in the absence or
presence of 32P-UTP to radioactively label probes. The USE60/DSE120, ΔUSE60/DSE120,
alt60/DSE120, USE60/alt120 and ΔUSE60/alt120 were created by PCR with primers (with a T7 tag
attached) to the respective minigene that contained the sequence. These were used as templates
for in vitro transcription without radio-label.
Nuclear extract and recombinant proteins
Nuclear extract was purified from JSL1 cells using a standard protocol previously described in
Lynch et al, 2001116. Recombinant his-tagged CELF2 was expressed in Rosetta (DE3) PLysS cells,
a BL21 derivative of E.Coli and were purified using Nickel-NTA resin (GE Biosciences) according
to company provided protocols. JSL1 cells stably expressing FLAG-CELF2 were grown under
unstimulated or stimulated conditions and then lysed to prepare nuclear extract. Tagged proteins
were purified from nuclear extract with EZ-View Red FLAG-conjugated resin (Sigma) in GFB300
(20 mM Tris-Cl, pH 7.5, 300 mM KCl, and 0.2 mM EDTA, pH 8.0). Following extensive washing in
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GFB300, the proteins were eluted with 500 ng/ul of 3X Flag peptide (Sigma). Protease and
Phosphotase inhibitor cocktails (Sigma) and de-acetylase inhibitor (Millipore) were used during the
purification.
Cell culture
JSL1 cells (Lynch et al, 2000)31 were cultured in RPMI+ 5% fetal calf serum at 37°C in 5% CO2.
Sub-lines of JSL1 cells that stably express the minigenes described were created by transfecting
10 million cells with 10 ug of minigene plasmid by electroporation and grown under drug selection
as described by Rothrock et al., 2003117. For splicing analysis, three independent clones of each
minigene were either left untreated or treated with 20 ng/ml of PMA for 60 h, after which cells were
harvested and total RNA extracted using RNABee (Tel-Test). Minigene derived spliced products
were analyzed by RT PCR using vector-specific primers (see below).
RT-PCR
RT-PCR and analysis was carried out as previously described in detail by Rothrock et al. 2003. In
brief, a low-cycle PCR protocol was used, such that the signal detected is linear with respect to
input RNA. Minigenes were analyzed using the vector-specific primers ACT and GE3R (sequence
published in Rothrock et al., 2003). Quantitation was done by densitometry using a Typhoon
Phosphoimager (Amersham Biosciences).
Western blotting
Western blotting was carried out as previously described in Lynch et al, 2000. Antibodies for
Western blots were as follows: anti-hnRNP L (4D11, Abcam), anti-CELF2 (HL1889, University of
Florida Hybridoma Lab), anti-hnRNP C, (ab10294, Abcam), anti-hnRNP F/H (ab10689, Abcam),
anti-hnRNP F (ab50982, Abcam), anti-hnRNP H (ab10374, Abcam).
in vitro splicing assay
Unlabeled RNA substrates (10 nM) were incubated with 30% unstimulated JSL1 nuclear extract
in a total volume of 12.5 μl under splicing conditions, which contains (final concentration):
12 mM Tris-HCl, pH7.5, 3.2 mM MgCl2, 4 mM ATP, 20 mM CP, 0.5 mM DTT, 0.125U
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RNasin (Promega), 60 mM KCl, 0.1 mM EDTA, and 12% glycerol. Reactions were incubated for
90 min at 30°C; then the RNA was recovered from the reactions by proteinase K treatment, phenolchloroform extraction and EtOH precipitation. The recovered RNA was analyzed by RT-PCR.

RNA electro-mobility shift assays (EMSA)
in vitro transcribed RNAs were gel-purified and adjusted to 104 cpm/ml specific activity. Each RNA
was incubated with US or S FLAG-CELF2 or his-CELF2 in a total volume of 10ul under splicing
conditions similar to that described for the in vitro splicing assays with the addition of 0.8 mg of
BSA and 0.8mg. Reactions were incubated for 20 min at 30°C, after which heparin was added to a
final concentration of 5 mg/ml and incubated for an additional 5 min at 30°C. Reactions were
analyzed on a 4.5% native gel (Acrylamide/Bis 29:1 BioRad) and visualized by autoradiography.
UV Crosslinking
Radiolabeled RNA was incubated in JSL1 nuclear extract under similar conditions described for
the EMSAs. Reactions were incubated for 20 min at 30°C, crosslinked using UV light (254 nm) for
20 min on ice, and digested with 2 ug (final concentration) of RNase T1 and RNase A each for 20
min at 37°C. Reactions were analyzed under denaturing conditions on a 12% gel (Acrylamide/Bis
37.5:1, BioRad), and visualized by autoradiography.
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APPENDICES

Appendix A: Analysis of CELF2’s co-associated proteins
FLAG-CELF2 was IP’ed using it’s FLAG-tag from US and S JSL1 cells in the absence of Rnase.
The proteins that co-IPed with CELF2 were was analyzed using mass spectrometry in
collaboration with the Wistar Institute. Some of these interactions were compared with proteins
that co-IPed with FLAG-CELF2 in the presence of RNase to determine which of them were direct
interactions and which of them required RNA. The figure below summarizes western blots that
probe these interactions in the presence and absence of RNase in the US and S state. They also
contain spectral counts from the mass spectrometry results.
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Appendix B: in vitro splicing in the presence of US and S FLAG-CELF2
in vitro splicing assays as performed in Chapter 4 Figure 4.1 were repeated with increasing
amount of US or S FLAG-CELF2 protein. Although the fold change in splicing upon addition of
280 ng of US or S FLAG-CELF2 was only significant between the alt60/DSE120 and
USE60/alt120, the trends for all comparisons support the hypothesis US-CELF2 is repressive and
S-CELF2 is activating. Whether this is due to change in PTMs or the influence of another protein
is yet to be determined.
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Appendix C: UV crosslinking in nuclear extract
1. Set up binding reaction:
4 ul Nuclear Extract, protein or buffer (BC100 or BC300)
1 ul BC400
1 ul tRNA/BSA/BC100 mix (0.25ug/ul tRNA + 0.2 ug/ul BSA in BC100)
0.4 ul 80mM MgCl2
0.4 ul 25mM ATP
0.4 ul 0.5M creatine phosphate (CP)
1 ul H2O
1 ul radiolabeled RNA
2.
3.
4.
5.
6.
7.
8.

Incubate binding reaction at 30oC for 20 minutes
Pipet reactions into a 96-well U bottom plate on ice (keep top off plate)
Place handheld 254nm lamp overtop, cover in aluminium foil and crosslink for 20 minutes
Pipette reactions into new Eppendorf tubes that contain 20U RNase T1 + 20ug RNase A
Digest at 37oC for 20 minutes
Add 13ul 2xSDS sample buffer and 1.3 ul 2-ME
Boil samples for 5 minutes and load on 10% SDS-PAGE gel (30 ml)

75

Appendix D: UV crosslinking in nuclear extract with immuno-precipitation
UV Crosslinking with Immuno-Precipitation (IP)
1. Set up binding reaction (use 2-4 reactions per IP):
4 ul Nuclear Extract
1 ul BC400
1 ul tRNA/BSA/BC100 mix (0.25ug/ul tRNA + 0.2 ug/ul BSA in BC100)
0.4 ul 80mM MgCl2
0.4 ul 25mM ATP
0.4 ul 0.5M creatine phosphate (CP)
1 ul H2O
1 ul radiolabeled RNA
2. Incubate binding reaction at 30oC for 20 minutes
3. Pipet reactions into a 96-well U bottom plate on ice (keep top off plate)
4. Place handheld 254nm lamp overtop, cover in aluminium foil and crosslink for 20
minutes
5. Pipette reactions into new Eppendorf tubes that contain 20U RNase T1 + 20ug
RNase A
6. Digest at 37oC for 20 minutes
7. Pool 2-4 identical reactions in Eppendorf tube
8. Add 5-10 ul antibody
9. Bring volume to 400 ul with 1xRIPA buffer
10. Rotate overnight at 4oC
11. Add 40 ul Protein-G sepharose beads pre-washed in 1xRIPA buffer
12. Rotate 1 hour at 4oC
13. Spin down at 0.8g for 30 seconds and wash 3x with 1xRIPA buffer
14. After last wash, remove buffer and resuspend beads in
15. Add 13ul 2xSDS sample buffer and 1.3 ul 2-ME
16. Boil samples for 5 minutes and load on SDS-PAGE gel
1xRIPA
50mM TRIS pH 8
1% NP-40
0.5% sodium deoxycholate
150mM NaCl
0.1% SDS
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Appendix E: PCR for making DNA templates for in vitro transcription
Forward Primers (FP), Reverse Primer (RP) and Plasmids:
in vitro splicing - 2-exon constructs:
Construct
FP
RP
Plasmid
USE60/DSE120 SA60 Adml BamHI R Adml LEF1 S5
USE60/alt120
SA60 Adml BamHI R Adml LEF1 S7m
alt60/DSE120
SA68 Adml BamHI R Adml LEF1 S11
Δ/DSE120
SA58 Adml BamHI R Adml LEF1 S5
Δ/alt120
SA58 Adml BamHI R Adml LEF1 S7m
alt60/alt120
SA68 Adml BamHI R Adml LEF1 43
EMSAs:
Construct
4xUGUU
DSE120
UV crosslinking
Construct
USE60/DSE120
USE60/alt120
alt60/DSE120
alt60/alt120
Δexon
ΔDCS

FP
SA34
SA34

FP
SA44
SA44
SA69
SA69
SA44
SA44

RP
SA35
SA35

RP
SA65
SA55
SA65
SA55
SA65
SA65

Plasmid
LEF1 S32
LEF1 S5

Plasmid
LEF1 S5
LEF1 S7m
LEF1 S11
LEF1 S43
LEF1 S14
LEF1 S45

Set up 3 reactions per construct.
1 x reaction:
30 ul H2O
5 ul
10xPfu buffer
10 ul 1mM dNTPs
1.25 ul 100ng/ul FP
1.25 ul 100ng/ul RP
1 ul
100ng/ul Plasmid (see above table)
1 ul
Pfu
PCR Program:
1. 94oC 2 min
2. 94oC 45 sec
3. 45oC 45 sec
4. 72oC 45 sec
repeat 2-4 for 34 cycles
5. 72oC 10 min
6. 4oC
hold
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Run all reactions on a 1% agarose gel. Cut out band corresponding to the right size and
extract the DNA from the gel using Qiagen’s gel extraction kit. Use 25 ul ddH2O to elute
DNA of column. You will usually need two columns per construct. Concentration of
eluted DNA is between 50-80 ng/ul.
NOTE:
USE60 and 2xUGUU constructs were created by linearizing plasmid DNA (pcAT7
USE60 and pcAT7 2xRTB) with HINDIII.
Reaction:
10 ul plasmid
20 ul 10xBuffer
5 ul
HINDIII
165 ul H2O
Incubate for 2 hours at 37oC. PCA extract and resuspend in 10ul ddH2O.
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Appendix F: in vitro transcription to create non-labeled or radio-labeled RNA for in
vitro splicing, EMSAs or UV crosslinking assays
1. Thaw all stock reagents to room temperature before use.
2. For each transcription reaction refer to table below. Add DNA to tubes first.
Create master mix of remaining ingredients (except P32-αUTP) and add
appropriate amounts to tubes with DNA. Add exact amount of P32-αUTP at the
end.
Stock Reagents

Template DNA, PCR (~50100ng/ul)
5x transcription buffer (Promega)
10xACG mix (8, 8, 2 mM)
20mM UTP
100mM DTT
25mM CAP
Rnasin (Promega)
T7 RNA polymerase
Total

non-labeled
(in vitro
splicing)
9.7 ul
5 ul
2.5 ul
1 ul
2.5 ul
0.8 ul
1 ul
2.5 ul
25

Stock Reagents

radio-labeled
(EMSA, UV
crosslinking)

Template DNA, PCR (~50-100ng/ul) or 1000 ng
(linearized)
5x transcription buffer (Promega)
10xACG mix (8, 8, 8 mM)
20mM UTP
100mM DTT
P32-αUTP (3.3pmol/ul)
Rnasin (Promega)
T7 RNA polymerase
autoclaved H2O
Total

5.5 ul or 1 ul
5 ul
2.5 ul
0.25 ul
2.5 ul
5 ul
1 ul
2.5 ul
0.75 ul or 5.25 ul
25

3. Incubate at 37oC for 3-4 hours
4. Add 1ul RQ1 DNase and incubate at 37oC for 15 minutes
5. Add 175 ul H2O to each reaction. Then add 200 ul PCA alcohol, shake
vigourously and spin at max speed for 5 minutes
6. Transfer top layer carefully to a new eppendorf and ethanol precipitate by adding
1 ul glycogen, 500 ul 100% EtOH, 20 ul 3M NaOAc.
7. Freeze at -20oC for 1 hour
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8. Spin at max speed for 15 minutes
9. Wash pellet with 750 ul 75% EtOH
10. Re-suspend pellet in 8ul F dye and boil for 5 mins
11. Load samples onto 4% PAGE gel and run at 1200V until bottom dye reaches end
of the gel but doesn’t run off.
12. Cut out bands from gel and transfer to new Eppendorf
13. Use the tip of a pipette tip to break apart the gel piece
14. Add 400 ul elution buffer (0.1%SDS in TE buffer) and rotate overnight at room
temperature
15. Briefly spin down the gel and transfer the supernatant into a new tube.
16. Add 400 ul PCA alcohol, shake vigourously and spin down at max speed for 5
mins
17. EtOH precipitate as in steps 6-9
18. Carefully remove last amounts of EtOH and resuspend pellet in 10 ul ddH2O.
19. Use 1 ul to measure concentration (non-labeled) or use in a scintillation counter
(radio-labeled).
20. Dilute to: in vitro splicing = 1 ng/ul, UV crosslinking = 1x105 cpm, EMSA = 1x104
cpm

80

Appendix G: in vitro splicing without CELF2 protein
Per 13 ul reaction (for either radio-labeled or non-labeled RNA substrate):
0.5 μl 80mM MgCl2
0.5 μl 25mM ATP
0.5 μl 0.5M CP
0.5 ul BC850
3 ul
13% PVA
3 ul
BC100
4 μl
Nuclear Extract
1 μl RNA substrate (final concentration: 8~10 fmol/ μl = 8~10 nM, 1ng/ul)
1. Mix everything except RNA (master mix) and then add the 12 μl of the master mix into
the tube with 1 μl RNA substrate. (everything on ice).
2. Incubate at 30 °C for 90 minutes (or desired amount of time). Add 175 μl proteinase K
treatment mix, flick tubes several times to mix well and incubate for 15 minutes at 30°C.
(PK treatment per reaction = 100μl 2X PK buffer, 71μl H2O, 2.5μl proteinase K (20mg/ml
stock), 1.5ul Glycogen)
3. Following PK treatment, PCA alcohol extract, ethanol precipitate and 70% ethanol wash.
4. Resuspend the pellet in 10 μl H2O. Store at -80 °C, or continue on with the RT-PCR
analysis
2X PK buffer
20mM Tris pH7.5
200mM NaCl
25mM EDTA
2% SDS

RT-PCR assay for in vitro splicing reactions with constructs USE60/DSE120, alt60/DSE,
USE60/alt120, Δ/DSE120, USE60/Δ:
Forward Primer: SA16 (sequence in LEF1 exon 6)
Reverse Primer: Adml BamHI R (sequence in Adml exon 2)
PCR program:
1. 94°C 2 min
2. 94°C 1 min
3. 70°C 1 min
4. 72°C 1 min
repeat 2-4 for 25 cycle
5. 72°C 5 min
6. 4°C
hold
Expected splice products: spliced RNA= 338nt; spliced RNA = 128nt

Electromobility Shift Assay (EMSA)
1. Cast 4.5% monomer gel and allow to polymerize for an hour
2. Set gel to pre-run for 20 minutes at 150V. In the meantime set up the binding reactions.
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3. Binding conditions per 10 ul reaction:
1 ul
1 ul
0.9 ul
0.4 ul
0.4 ul
0.4 ul
0.1 ul
0.8 ul
3 ul
1 ul
4.
5.
6.
7.
8.
9.
10.

13% PVA
tRNA/BSA mix in H2O(0.25ug/ul yeast tRNA and 0.2ug/ul BSA)
10mM DTT
80mM MgCl2
25mM ATP
0.5M CP
RNasin
ddH2O
BC300 or CELF2
labeled RNA probe

Aliquot 8 ul of master mix to each reaction on ice
Add 3 ul his- or FLAG- CELF2 (in BC300)
Add I ul 32P-αUTP labeled RNA probe (at 104 cpm/ul)
Incubate at 30oC for 20 minutes
Transfer reactions to ice. Add 1 ul heparin (5 ug/ul) to each reaction
Load entire reaction on a 4.5% monomer gel and run at 150V for 1.5 hours
Transfer to whatman paper, dry gel and detect by autoradiography.

4.5% monomer gel
45 ml
ddH2O
6 ml
5xTBE buffer
9 ml
30% acrylamide (29:1)
500 ul
20% APS
50 ul
TEMED
BC300
20mM TRIS pH 7.5
0.2mM EDTA
300 mM KCl
20% glycerol
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Appendix H: FLAG-CELF2 purification with protease, phosphatase and deacetylase inhibitors, RNase and DNase
1. Grow 30L of FLAG-CELF2 expressing JSL1 cells (15L for unstimulated and 15L for
stimulated). Stimulate using 2xPMA concentration normally used for 6 well plates.
2. Harvest cells at 3000 rpm, 15 minutes, 4oC.
3. Wash cells with 200ml cold PBS in 250ml conical tubes. Spin at 3000rpm, 15’, 4oC.
4. Assess Packed Cell Volume (PCV). Determine 5x PCV of Buffer A
5. Resuspend pellets in 5xPCV buffer A. Incubate on ice for 10’. Spin @ 4000rpm, 15’, 4 oC
6. Discard supernatant. Resuspend pellets in 2xPCV of Buffer A. Dounce 10 strokes with
pestle A.
7. Transfer dounce-ate to new SS34 open tubes and spin 3000rpm, 10’, 4oC
8. Remove supernatant (S100). Respin tubes at 16500rpm, 20’, 4oC
9. Add HALT Protease and phosphatase inhibitor cocktail (100x, Thermo-Fisher), sodium
butyrate (de-acetylase inhibitor, Millipore), 15 ul DNase and 15 ul RNase to 0.7xPCV
buffer C
10. Discard supernatant. Resuspend pellets in 0.7xPCV each. Dounce 10 strokes with Pestle
A
11. Transfer to conical tube and rock at 4oC for 30’. Transfer to SS34 tube and spin 16500
rpm, 30’, 4oC
12. In the meantime, equilibrate 750ul each (for US and S) FLAG beads in TBS. (3x, 8200g,
30’’)
13. Remove and save supernatant from 11). Measure volume of sup and dilute 2x with Buffer
F.
14. Add diluted nuclear extract to flag beads in conical tube and rotate at 4oC for 1 hour.
15. Dilute 3x flag peptide to 300ug/ml in TBS (300mM KCl).
16. Spin in Tissue culture room centrifuge @ 4000rpm, 1min, 4oC
17. Remove supernatant (unbound). Resuspend beads in TBS (300mM KCl), transfer to a
micro-centrifuge tube. Rotate for 5mins and spin at 8200g, 30s. Repeat 3 times.
18. Elute, in batch, 4 times with 3x Flag peptide (300ug/ml). (Same as wash)
19. Re-spin all eluants at 13500rpm for 1 min to pellet residual beads. Transfer sup to new
tubes.
20. Take 20ul total (10ul for each gel) and run gels for coomassie and westerm staining.
Upon confirming fractions with CELF2 protein – Dialyze into BC300 Buffer. – 3 Hours.
21. Take another 10ul from each dialysis and run Coomassie and if enough volume, another
10 for a western.
22. While gel is running, freeze samples down (dry ice) in 11ul aliquots.
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Appendix I: his-CELF2 expression and purification
1. Transform His-CELF2 into Rosetta pLysS cells. Plate out a couple of different dilutions.
2. Pick one colony for an O/N culture into 50ml of 2xYT with 1:1000 dilutions of Kanamycin
and Chloramphenicol
3. Make a 1:100 dilution of above culture into 500ml 2xYT (with KAN and CHL). Grow cells
till A600=0.8.
4. Induce with 1mM IPTG for 3 hours at 37oC.
5. Add 250ul of 1M PMSF to each culture and centrifuge at 4000rpm for 10 mins.
6. Resuspend Pellet in 20ml Buffer A and freeze both at -80C.
7. Thaw pellet in Room Temperature water bath until a small amount of ice is remaining.
Transfer pellet to ice to finish thawing
8. Sonicate using wand lab sonicator (3x) with 1 min cool down in between sonications
9. Centrifuge at 26000rpm for 1 hour. Separate supernatant from pellet. Take gel samples
from both.
10. Equilibrate 50ul Ni-NTA beads (50% slurry, so 100ul total) in Buffer A. (resuspend 1ml
buffer A, 1000xg for 10s – 3x)
11. Add 1ml of supernatant to beads and rotate at 4C for 30mins. Freeze the rest of the
supernatant at -80 for scale up purification
12. Centrifuge at 1000xg for 10s. Remove Supernatant (Flowthrough)
13. Wash beads with Wash buffer (Buffer A +10mM additional Imidazole) 3x
14. Resuspend beads in Sample buffer
15. Run all samples on SDS-PAGE gel
16. Based on amount of protein bound to beads and left in flowthrough, adjust bead volume
and scale up purification with the rest of the lysate from step 6.
17. For scale up - elute protein off of beads in Buffer A + 250-500mM Imidazole.

Buffer A:
50mM Na Phosphate
300mM NaCl
10mM Imidazole
10mM BME
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